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ABSTRACT
THE INFLUENCE OF MIR-99A ON MTOR SIGNALING REGULATION IN
COLORECTAL CANCER CELL LINES
Jonathan Rice
22nd May, 2015
Colorectal cancer (CRC) is the third most common cancer worldwide and the
fourth most common cause of death. These are staggering statistics for a disease that can
essentially be cured if caught early and the pathology is favorable to therapeutic
intervention. There is currently a drastic decrease in five year survival as the cancer stage
increases from locally confined disease to metastatic disease. These statistics suggest that
although some strides have been made with colon cancer screening and early
intervention, there is still much room for improvement in both screening and treatment of
CRC.
One of the pathways that have been linked to CRC is the mammalian target of
rapamycin (mTOR) pathway. Recently this has been the subject of intense study
particularly with a view to better targeted drug therapy for colorectal cancer. Much is
known about this pathway; however, multiple regulatory elements have yet to be
elucidated. MicroRNAs (miRNAs) have been shown to influence some aspects of the
mTOR pathway in other cancers, however their role in the mTOR pathway in CRC has
v

yet to be fully explored. The microRNA-99 (miR-99) family of miRNAs has recently
been implicated in regulation of mTOR signaling in other diseases.
Studies were conducted using normal colon epithelial and CRC cell lines provided the
following key findings:
1. Transfection of miRNA-99a mimic into CCD-841 (normal epithelium) and
CRC cell lines, HT-29 (Dukes C), HCT-116 (Dukes D), results in a decrease
in the amount of phosphorylated mTOR protein in all 3 cell.
2. miRNA-99a transfection also affected expression of downstream protein
products, with a decrease phosphorylated S6K1 in HT-29 and CCD-841,
while this same transfection showed an increase in this phosphorylated protein
in cell line HCT-116. The opposite was observed for protein 4EBP1 after
transfection, which showed an increase in phosphorylated 4EBP1 in cell lines
HT-29 and CCD-841, but a decrease in phosphorylated protein the HCT-116
cell line.
3. Transfection of miRNA-99a mimic resulted in decreased motility and
invasion in cell lines HT-29 and HCT-116 as compared to cell lines
transfected with the negative control. Transfection with the miRNA-99a
antagomir resulted in increased motility in both CRC cells lines but minimal
changes or decrease in invasion.
The effects of miRNA-99a on mTOR protein, S6K1 and 4EBP1 were elucidated
by this project providing further evidence as to the importance of mTOR inhibition for

vi

possible regulation of CRC metastasis. This supports new avenues of study to further
understand CRC metastasis as well as possible targets for therapeutic intervention.
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CHAPTER 1
COLORECTAL CANCER: A SIGNIFICANT CLINICAL PROBLEM
A. EPIDEMIOLOGY
Colorectal cancer is a major cause of morbidity and mortality. As of 2011, it was
the third most common cancer worldwide and the 4th most common cause of death.1 In
the United States, in 2013, it was the third most common cancer among men and women
accounting for 96,830 new cases of colon cancer and 40,000 new cases of rectal cancer
and in turn 50,310 colorectal cancer deaths annually.1 These statistics suggest that
although some strides have been made with colon cancer screening and intervention,
there is still much room for improvement in both screening and treatment.

1

Distribution

5-year Survival

Figure 1: 5 Year Survival and Distribution of Colorectal Cancer Based on
Location of Disease
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B.

STAGING

Table 1: Colorectal Cancer Staging
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C.

SCREENING
Early screening appears to have led to a delayed but meaningful reduction in

disease mortality. Although this is a significant advance for clinicians and their patients,
the side effects and preoperative preparation that are involved in colon and rectal cancer
screening leads to significant cost to the health care system and personal morbidity to the
patient.2
Current recommendations for colon cancer screening for patients that are not a
“high risk” for colon cancer begins at the age of 50 and continues until the age of 75.3
There are currently 3 accepted screening tests; each has its benefits and downsides, each
occurring at different intervals. The first screening test is the high-sensitivity fecal occult
blood test, which is recommended once yearly. The upside of this is the lack of invasive
nature and no need to undergo bowel preparation; the downside of this test is it is not
specific for colon cancer and detects any blood that is in one’s gastrointestinal tract. The
second screening test is flexible sigmoidoscopy. The recommended interval of this test is
every five years with the addition of fecal occult blood test done every three years. The
advantage of this test is the clear visibility of the lower part of the colon and rectum, but
the downside is its invasiveness and patient discomfort. In addition, the clinician is
unable to visualize the entire colon. Colonoscopy is the currently accepted “best
screening” method and most complete screening test. It is recommended every 10 years
for patients who are not at high risk. The benefits of colonoscopy are complete
visualization of the colon and potential intervention when polyps are detected. Downsides
of colonoscopy include the laxative bowel preparation for this procedure, the risk of
bowel perforation and operator skill set, both with respect to completeness and safety. To
4

state the obvious, colonoscopy does not come without risk. The unpleasant nature of this
bowel preparation leads to imperfect compliance and reduces the effectiveness of the
colonoscopy itself.
D.

TREATMENT OPTIONS
Current therapy focuses on endoscopic and surgical intervention.3 The additions

of chemotherapy and radiation therapy come into play when regional or distant metastasis
are a factor. Due to the advances over the last several decades in endoscopic surveillance,
more cases of colon cancer are detected at an early stage prior to metastasis.3
Early stages of colon cancer are treated and may be cured with polyp removal.
This is why screening colonoscopies are so important- because when a polyp is
recognized and removed prior to the polyp converting to an invasive mass, it can be
essentially “cured” at the time of endoscopy. If the polyp progresses to an invasive,
cancer but has not metastasized to the lymph nodes, this also can be treated with surgical,
often laparoscopic, resection (Figure 2). Colon cancers can be treated with segmental
colectomy and anastomosis, frequently leading to patient cure.

5

Figure 2. Colorectal Cancer Progression from Benign Polyp to Invasive Tumor
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E.

CASE SCENARIOS ILLUSTRATING LIMITATIONS OF CURRENT
SCREENING GUIDELINES
With a variety of screening tests whose goal is early intervention, there are still

clinical scenarios where large bowel tumors are missed for several reasons. This can be
illustrated in the following two clinical scenarios.

Case 1
A 48 year old woman presents to her primary care physician with a
several week history of blood seen in her stool. She undergoes a focused
history and physical. She does not have a family history of any cancer or
disease processes. She denies weight loss but does state that her bowel
movements have been somewhat irregular as of late. Upon physical exam,
her doctor does notice some external hemorrhoids with some blood on
them. Since she does not have a family history of colon cancer and she is 2
years away from recommended “normal screening” for colon cancer, the
doctor attributes the blood seen in the stool to the current hemorrhoids and
provides treatment for this.
The same patient returns 2 years later, now with weight loss and
lack of energy. She has not had any other blood noticed in her stool since
her visit 2 years prior. Now that she is 50, and due to the nature of weight
loss and weakness, her physician now recommends a screening
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colonoscopy, during which a large partially obstructing cancer is seen in
her transverse colon. In her evaluation prior to resection, a liver lesion is
noticed. She is optimized for her operation and upon elective operation is
found to have a bulky transverse colon cancer which is resected with a
primary anastomosis; the lesion in the right lobe of her liver is biopsied
and the mass is found to be adenocarcinoma consistent with colon cancer.
She now requires systemic chemotherapy and/or a major liver resection
for this metastasis. Her likelihood of surviving 5 years is less than 40%.
Case 2
A 60 year old woman has a several day history of blood in her
stool. She presents to her primary care physician who performs a history
and physical examination. Her most recent colonoscopy was 10 years ago
and no polyps or masses were observed at the time. Since her last
colonoscopy was 10 years ago and she is “due” for a screening exam, her
personal physician schedules her for this procedure. During the
colonoscopy, she is noted to have a locally advanced cancer in her
sigmoid colon. She is subsequently scheduled for further evaluation and
operative resection of the cancer and primary anastomosis. She recovers
from her operation and the pathology reports show adenocarcinoma that
has penetrated the bowel wall but is free of metastasis in the 16 lymph
nodes removed intraoperatively. At 6 month follow up, she remains well
and her primary relatives are notified by the patient of these events, since
all relative now have a “positive” family history.
8

Both of the above scenarios would benefit from a more accurate screening
examination to determine if an individual needs colonoscopy sooner than the
recommended interval screening. In Case 1, the individual is “two years too young” for
the recommended screening age, yet if a simple blood based test could tell the clinician of
a possible polyp or cancer, then intervention could presumably be undertaken prior to
development of a distant metastasis. Intervention prior to metastasis is key, as the 5 year
recurrence rate for colorectal cancer drastically increases once distant metastasis is
present.
F.

CURRENTLY AVAILABLE PLASMA-BASED BIOMARKERS FOR
COLORECTAL CANCER
Carcinoembryonic antigen (CEA) assay is the most popular assay for clinical

monitoring. It has been used for post-operative surveillance and for monitoring response
to therapy. CEA, however, lacks sufficient sensitivity and specificity for screening or for
detecting CRC recurrence.4 It also has been used as a prognostic marker. CEA is
normally elevated during the fetal development period but beyond that, it is not normally
found in the blood. CEA levels may increase with distant metastasis but this assay does
not have high specificity or sensitivity in regards to detection of distant metastases. In
addition, CEA can be elevated in many other types of cancer, as well as falsely elevated
in smokers.
Carbohydrate antigen 19-9 (CA 19-9) has been used as a prognostic tumor marker, but it
is less sensitive than CEA for CRC.5 Methylated septin 9 has been reported to have good
sensitivity and specificity for CRC but does not have sufficient ability to detect colorectal
adenomas.6 Markers in development include CSA (colon cancer specific antigen)-1, 2

9

and 3, colon-cancer-secreted-protein (CCSP)-2,7,

8

galectin-3-ligand and haptoglobin-

related-glycoprotein.
Unfortunately, no accurate, broadly applicable test currently exists for colorectal
adenomas that could identify candidates for intervention (colonoscopic removal) in order
to prevent CRC or to diagnose CRC at an earlier stage (Table 2 a&b). This has been a
focus of work in the Price Institute since 1995.

10

Table 2. 5 year Survival Rates of Colon and Rectal Cancer
A. Colon Cancer by Stage
5 Year Survival Rate
Stage
I
II A
II B
III A
III B
III C
IV

Survival Rate (%)
92
87
63
89
69
53
11

B. Rectal Cancer by Stage
5 Year Survival Rate
Stage
I
II A
II B
III A
III B
III C
IV

Survival Rate (%)
87
80
49
84
71
58
12

*National Cancer Institute's SEER database, looking at people diagnosed with colon and
rectal cancer between 2004 and 2010
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CHAPTER II
PRELIMINARY DATA : MIRNA AS BIOMARKERS FOR COLORECTAL CANCER
A.

MIRNA OVERVIEW
miRNAs are short noncoding RNA molecules that range from approximately 19-

23 nucleotides in length. They bind to complementary sequences on target messenger
RNAs (mRNA). The affinity of binding can influence the effect of the miRNA on
mRNA. miRNAs can cause translational repression, target sequence degradation and or
gene silencing to name a few of their functions (Figure 3). miRNAs are a promising area
to research because of their inherent stability intra- and extra-cellularly. Furthermore,
they are known to be involved in numerous regulatory processes in the human body and
have been shown to be sensitive and specific biomarkers in some cancers and other
human diseases.

12

Figure 3. miRNA processing from nucleus to cytoplasm2, 9

Billeter et al. Semin Thorac Cardiovasc Surg. 201210

13

B.

TISSUE AND PLASMA MIRNA IN CRC, INITIAL STUDIES
Kanaan evaluated miRNA in both CRC tissue and normal mucosa. Levels of 380

miRNAs were determined using microfluidic array technology (Applied BioSystems) in a
“training” set of 30 CRC patients from whom cancer and nearby normal tissue were
collected. The 4 most dysregulated miRNAs (P < 0.05, False Discovery Rate (FDR):
10%) were then validated in a second blinded “test” set of 16 CRC patients from whom
cancer and nearby normal tissue had also been collected. Nineteen of 380 miRNAs were
dysregulated in CRC tissue in the tissue “training” set (P < 0.05, FDR: 10%). The 2 most
upregulated (miR-31; miR-135b) and most down-regulated (miR-1; miR-133a) miRNAs
identified CRC in our “test” set with 100% sensitivity and 80% specificity. MiR-31 was
also more upregulated in stages III and IV compared with stages I and II (P<0.05).11 The
most dysregulated tissue miRNAs were then validated in an independent new plasma test
set consisting of 20 CRC patients with 20 age- and race-matched subjects without CRC.
In the “plasma test” group, miR-21 differentiated CRC patients from controls with 90%
specificity and sensitivity. Although these early results were promising, miR-21 has been
described in other cancers. Thus, there is a need to develop a more specific plasma
miRNA panel for CRC.
C.
PLASMA MIRNA TO DETECT PREMALIGNANT LESIONS OF THE
COLON (ADENOMAS)
We studied colorectal polyps or colorectal advanced adenomas (CAA) with the
highest likelihood of malignant transformation over time. Advanced adenomas are
defined as adenomas >0.75 cm, with a villous component or high-grade dysplasia and

14

represent a continuum from benign adenoma to invasive CRC. We screened 380 plasma
miRNAs using microfluidic array technology (Applied BioSystems) in a screening cohort
of 12 controls, 9 patients with CAA, and 20 patients with stage III & IV CRC. A panel of
the most dysregulated miRNAs (P <0.05, FDR 5%) was then validated in a blinded
cohort of 26 controls, 16 patients with CAA, and 45 patients with CRC. After testing the
15 most dysregulated microRNAs in the validation group, a combined panel of miR-5323p, miR-331, miR-195, miR-17, miR-142-3p, miR-15b, miR-532 and miR-652 identified
CAA accurately. This 8-miRNA panel demonstrated an AUC of 0.868 [95% CI 0.760.98] in the plasma “validation” set, indicating good discriminative power. Additionally,
in the validation set, miR-139-3p and miR-431 were significantly dysregulated
differentiating controls from all CRC stages (AUC = 0.829 [95% CI: 0.73–0.93]) (Fig. 5).
Receiver-operating-characteristic (ROC) curves of miRNA panels for CAA versus all
CRC showed an AUC of 0.856 (95% CI: 0.75–0.97). miRNAs specific for CAA and
CRC were explored and identified. Sensitivity and specificity values are based on the
generated ROC curves for each miRNA panel.12
D.

DIFFICULTIES WITH ASSAY REPRODUCIBILITY
miRNA expression profiles have been shown to be unique to both the source

material (i.e. plasma, tissue, etc.) and the disease process being investigated. miRNA
profiles have, therefore, emerged as prospective biomarkers for cancer and many other
human diseases 13-17.
This has led to a rapid proliferation of miRNA research. Unfortunately, many
studies have been conducted without attention to standardization of methods or
reproducibility of results, particularly with respect to studies of plasma miRNA. In many
15

reports, it is difficult to deduce the actual methods used for analysis. This has led to the
use of different extraction protocols, and various methods of quantification and statistical
analysis, which, in turn, are a source of variability (Table 3). In part, due to this lack of
standardization, many different miRNAs have been reported to be associated with a given
disease process 15. There is ongoing controversy over the optimal analytic methods for
studies of miRNA in plasma.18

16

Table 3. Multiple sources of variability in microRNA data and literature search

Parameter

.

Source of Variability


Biologic Sample

12, 19-93

Tissue



Plasma




Preservation Method
- Formalin fixed-paraffin embedded
- Snap Frozen
Collection Method
- Laser caption microdissection
- Macrodissection (includes stroma)
Collection method (e.g. EDTA tube)
Method to isolate plasma

Other body fluids (urine,
cerebrospinal fluid, etc.)



Collection method





Immediate (within 24 h)
Delayed
Guanidinium thiocyanate-phenol chloroform based ( e.g.
Trizol LS, LifeTechnologies)
 Glass fiber filter-based methods (e.g. miRVANA,
Method of RNA extraction*†
Ambion)
 Phenol/guanidine-based with and silica membrane based
purification (e.g. miRNeasy, Qiagen)
 Total
Type of miRNA*
 Fractional (e.g. exosomal)
 Cyanine dye-based RT qPCR (SYBR® Green) detection
miRNA characterization
 Fluorogenic 5’ nuclease-based RT qPCR detection
 Deep sequencing
 Absolute (addition of exogenous miRNA e.g. C. elegans
miRNA)
Quantification*
 Relative (use of an internal reference e.g. RNU48,
RNU44, RNU47, RNU6, miR-16)
 Fixed threshold
Cycle threshold bar*†
 Variable threshold
 Paired t-Test
 Wilcoxon Signed Rank test
Statistical analysis*†
 Cycle Threshold ratios
 Rank-based
 Intra-operator comparisons
Reproducibility†
 Inter-operator comparisons
Symbols: *Items investigated in systematic literature review. † Items investigated in our proposed standard
methodologic technique.
miRNA Detection & Statistical Analysis

RNA Extraction

Time to extraction*†
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Since the discovery of miRNAs, their detection in blood has received much attention
due to the ease of access and ready availability of peripheral blood as compared to tissue
15

. Initially, we performed a systematic review of publications focusing on plasma

miRNA in order to ascertain what methods and reporting criteria were currently being
utilized. We then we used a panel of 11 selected miRNA to study the effect of time to
plasma extraction, method of RNA extraction, cycle threshold bar setting, intra-operator
variability , inter-operator variability and selection of housekeeping gene on data
obtained in plasma miRNA studies.94, 95 An in-depth description of our statistical analysis
is found in the analysis section, however a full statistical model-based approach, such as
analysis of variance or analysis of covariance (ANOVA or ANCOVA) was used to
analyze the data.94
1. SYSTEMATIC REVIEW
In order to determine the consistency and current status of methods reporting of
clinical studies of plasma miRNA, we retrieved original manuscripts published from July
1, 2013, until June 30, 2014. We utilized a single search engine (PubMed) without
language restriction using the following search words: plasma, microRNA, and human.
We excluded review articles, case reports, or non-English language articles. Remaining
articles were then obtained for review. These were then graded as to how many of the
following criteria were clearly documented in the Materials and Methods sections: 1)
time of plasma extraction, 2) method of RNA extraction, 3) type of miRNA used (total vs
exosomal), 4) method of quantification (external vs internal reference), 5) cycle threshold
bar setting, and 6) methods of statistical analysis (items denoted by * in Table 2).
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Of the 220 retrieved abstracts, 130 were excluded because they were reviews,
case reports, or non-English language manuscripts. Sixteen publications were
unobtainable through our library, leaving 74 manuscripts available for review. A
PRISMA flow diagram is shown in Figure 4 and data shown in Table 4.
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Figure 4. A PRISMA flow diagram illustrating the search strategy used94
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Table 4. Systematic review: 74 plasma miRNA publications July 1, 2013 - June 30, 2014.

Number of studies
(% of total 74 manuscripts
reviewed)

Methodologic Parameter Assessed
Time of Plasma Extraction
≤ 2h
>2h
Not Stated
Method RNA Extraction+
Trizol
miRNeasy
mirVana
Not Stated/Other
Type of miRNA used
Total miRNA
Exosomal miRNA
Cycle Threshold Bar Setting
Fixed
Variable
Not Listed
miRNA Quantification*
External reference
Internal reference
Not specified
Statistical Analysis Described 
t-test
Mann-Whitney
Receiver operating characteristic
(ROC) curves
Wilcoxon
ANOVA
Other

44 (59.5)
8 (10.8)
22 (29.7)
13 (17.6)
25 (33.8)
30 (40.5)
8 (10.8)
72 (97.3)
2 (2.7)
2 (2.7)
1 (1.4)
71 (95.9)
31 (41.9)
32 (43.2)
12 (16.2)
74 (100)
30 (40.5)
29 (39.2)
24 (32.4)
16 (21.6)
12 (16.2)
14 (18.9)

+ Some manuscripts utilized more than one method of RNA extraction.
* Some manuscripts used both an internal and external reference.
 Many manuscripts used multiple methods of statistical analysis.
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Although nearly one-third of studies did not mention time to plasma, in the vast
majority (nearly 58%), plasma extraction was completed ≤2h after phlebotomy. Most
authors used either Trizol, miRNeasy, or mirVana protocols for RNA extraction, and
nearly all publications used total miRNA rather than exosomal miRNA. Equal
proportions of manuscripts used internal and external references (43% and 42%,
respectively). The most commonly utilized internal reference miRNAs were miR-16 (12
publications) and RNU-6 (7 publications). Seventy-one of the 74 reviewed publications
did not describe the setting of the cycle threshold bar. All but 2 of the 74 (97%) papers
stated at least some aspect of their statistical methods, with many using multiple,
different testing methods as shown in Table 2. Among reviewed manuscripts, only 1 (1.4
%) listed all 6 assessed criteria 27-102.

2. MICRORNA SELECTION
An eleven miRNA panel with RNU6 as an internal reference was used. These
miRNAs were selected based upon unpublished data from our laboratory utilizing 380
miRNA arrays (Applied Biosystems, Carlsbad, California) to determine miRNA
expression in the plasma of 20 colorectal cancer (CRC) patients, and 10 patients each
with colorectal advanced adenoma (CAA)(adenomatous polyps> 0.6 cm in maximal
diameter), breast cancer (BC), lung cancer (LC), pancreatic cancer (PC), and 10 controls.
In order to determine sample size, the most important aspect is adjustment of the
significance level (alpha). For screening studies, we use Jung’s procedure to adjust the
alpha. Using the method of Jung to find about 5% of features to be significant at a false
detection rate (FDR) of 5%, the adjusted alpha will be 0.0038. With any two groups, a
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minimum of n1=10 and n2=10 using a two sample t test, we can detect at least 2.7 fold
means (which we have observed in our preliminary data sets) using the common standard
deviation at significance level of 0.0038 and power of 80%.
With respect to choice of number of miRNA in our panel, it was our expectation
that no more than 10% of miRNA would be differentially expressed between cases and
controls after adjusting the p values for multiple comparisons. Of these, in turn, one
would not expect more that 0.5 to 3% of miRNA to be able to accurately identify cases
and controls. Ten miRNA and one reference (housekeeping gene) miRNA were,
therefore, chosen (approximately 3%). Statistical analysis using ANOVA identified 11
significantly dysregulated miRNAs specific for colorectal neoplasia (Table 2). Multiple
test control was based on controlling the false discovery rate (FDR) at 10%. A logistic
regression model was established using the top up-regulated miRNAs and used for
predicting the adenoma and control groups for the validation data. The sensitivity and
specificity for this prediction were calculated. The receiver operator characteristic (ROC)
curves with area under the curve (AUC) values were microRNA-rated using current
versions of SAS 96 and R 97-99 (Figure 1a & b).

3. PATIENT POPULATION
The University of Louisville Institutional Review Board reviewed and approved
this study. Written informed consent was obtained from all subjects who were treated at a
single university-based colorectal surgery practice. The patient population consisted of 16
patients with colorectal advanced adenomas, and 16 patients without colorectal neoplasia
(controls). The patient groups were age-, race-, and gender-matched. Prior to patient
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treatment, 6 mL of peripheral whole blood was obtained in EDTA tubes (BectonDickinson, Franklin Lakes, NJ) via venipuncture from the adenoma group and from
individuals in the “control” group at the time of routine screening colonoscopy. The latter
group of individuals (n=16) had no colonic neoplasia or inflammatory bowel disease.
Blood was stored at 4ºC until plasma isolation. Plasma was isolated within 24 h of
venipuncture, unless noted otherwise (see section below “Time to Plasma Extraction”).
Patient demographics are displayed in Table 3 and did not differ between patient groups.

4. TIME TO PLASMA EXTRACTION
Five 6 mL aliquots of peripheral blood from 6 controls were obtained and stored
at 4ºC until extraction. Plasma was extracted at different time points: immediately (within
30 minutes after phlebotomy) and then at 12, 24, 48, and 72 h post-phlebotomy. Whole
blood was centrifuged at 600 relative centrifugal force (rcf) for 15 minutes in order to
isolate the plasma, which was then stored at -80ºC for later use. Once plasma was
isolated, it underwent downstream processing via the modified phenol/guanidine-based
lysis and silica membrane-based extraction technique (miRNeasy, Qiagen, Venlo,
Limburg).
Our proposed standard technique provided a comparison. When performing
plasma extraction from whole blood at different time points, we found that 6 miRNAs
showed no differences in ∆CT values. In contrast, 5 miRNAs expressed a statistically
significant difference in ∆CT values between immediate plasma extraction and extraction
≥ 24 h for 1 miRNA (miR-122), between immediate extraction and extraction after ≥48 h
for 2 miRNAs (miR 485-3p, miR-21), and for 2 miRNAs with extraction at 72 h (miR
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523, miR 218) (Table 5,). Based upon these data using the representative miRNA we
have analyzed, plasma extraction less than 12h after phlebotomy appears to provide
equivalent results to immediate (within 30 minutes of phlebotomy) extraction.

5. EFFECT OF REPEATED SAMPLE ACQUISITION
In order to determine whether there was a difference between samples when
plasma miRNA were analyzed in samples drawn at different times from the same
individual, 6 mL peripheral blood was drawn from each of 12 healthy subjects without
any neoplasia or inflammatory condition at 6:30 AM and 12 hours later at 6:30 PM on the
same day. Plasma was extracted within 30 minutes of phlebotomy, and stored at -80ºC
for later use. Downstream processing was performed using the modified
phenol/guanidine-based lysis and silica membrane-based extraction technique
(miRNeasy, Qiagen, Venlo, Limburg) and methodology described below.
Repeated phlebotomy of the same individuals at 12-hour intervals showed no
differences in miRNA expression values (Table 5).
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Table 5. Effect of Repeated Sample Acquisition. Comparison of mean CT’s for
various plasma miRNA from plasma samples drawn from the same 7
individuals on the same day 12 hours apart.

miRNA

CT(mean) p-value

miR-374

-0.4458

0.454

miR-142-3p

-0.4136

0.4322

miR-523

-0.5518

0.3424

miR-374-5p

-0.2611

0.6425

miR-376c

-0.4312

0.5867

miR-27a

-0.3863

0.4776

miR-520d-5p

-0.3081

0.7506

miR-122

-0.0856

0.9251

miR-485-3p

-0.2611

0.6392

miR-21

-0.3976

0.5261

miR-218

-1.332

0.1659

miR-374

-0.4458

0.454
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6. METHOD OF RNA EXTRACTION
Total RNA was extracted from 250 µL plasma samples using either the TRIzol®
LS reagent protocol (Ambion, Austin, Texas), which was modified by addition of an
extended overnight drying period, or by a modified miRNeasy (Qiagen, Venlo, Limburg)
extraction technique with yeast carrier 100, 101. When using the TRIzol® LS total RNA
extraction technique, pre-amplification was necessary, as the majority of samples yielded
quantities of total RNA < 500 ng. In our experience, this is the minimum amount needed
for adequate expression and amplification in qPCR. The Applied Biosystems protocol for
producing custom reverse transcription and pre-amplification pools with TaqMan®
miRNA assays was followed. Total RNA purity was assessed using a Nanodrop 2000
spectrophotometer (Thermo Scientific, Middlesex, MA).
The Qiagen miRNeasy extraction without pre-amplification resulted in a higher
yield of RNA than Trizol LS extraction; therefore, pre-amplification was not necessary
and could be omitted as a source of possible variation (Table 6). The average ∆CT was
lower with miRNeasy, with fewer missing values than with Trizol purification and preamplification. Qiagen miRNeasy extraction without pre-amplification resulted in only 1of
704 (0.14%) miRNAs not expressing; however, utilizing the Trizol LS extraction with
pre-amplification, 109 of 704 (15%) of miRNAs investigated were not expressed (Table
7). A heat map showing miRNA expression for patient groups is shown in Figure 5. A
Step-One Plus RT-PCR System (Life Technologies, Carlsbad, California), with default
fast thermal cycling conditions, was used for RT-PCR. Individual Taqman probes (20x)
were used during RT-PCR to bind to a complementary sequence in the target cDNA.
These values were, in turn, normalized to the expression of the endogenous miRNA
27

RNU6 as internal reference to calculate ΔCT values for all studies except where
indicated.
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Table 6. Total RNA concentration and purity for Trizol LS and Qiagen miRNeasy with RNA yeast carrier.

Trizol LS
Qiagen
miRNeasy with
RNA Yeast
Carrier

Mean Total
Number of
RNA
Samples Concentration
(±SD)
32

19 (±12) ng/µL

32

353 (±85)
ng/µL

*p-value for mean total RNA concentration between methods

Mean
Average Purity
Total RNA
(±SD)
p-value*
Amount
[A260/A280]
380 ng

2.03 (±0.72)
<0.0001

7060 ng

1.95 (±0.13)
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Total RNA
Extraction
Method

Table 7. Inter-operator variability with two different extraction methods. Differences in ΔΔCT between Qiagen miRNeasy with RNA
carrier and no pre-amplification and Trizol LS with pre-amplification.

Qiagen miRNeasy w/o
Preamplification
# miRNA
Mean |ΔΔCT|*(±SD)
Not Expressed
0.70 (±0.78)
0

p-value

Mean
|ΔΔCT|*(±SD)
1.69 (±1.32)

# miRNA
Not Expressed
0

miR-142-3p
miR-523
miR-374-5p
miR-376c

1.69 (±1.83)
1.45 (±1.45)
1.69 (±1.73)
2.42 (±1.42)

0
0
5
22

0.91 (±0.89)
1.38 (±1.02)
1.27 (±1.06)
0.76 (±0.91)

0
0
0
0

<0.0001

miR-27a
miR-520d5p
miR-122

1.29 (±1.23)

6

0.98 (±1.03)

0

0.2786

31

1.20 (±1.01)

1

0.0405

1.82 (±1.86)

13

1.11 (±1.10)

0

0.0642

miR-485-3p

1.45 (±1.45)

0

1.50 (±1.01)

0

0.8734

miR-21

2.40 (±1.82)

0

1.36 (±1.00)

0

0.0062

miR-218

1.77 (±1.79)

1.09 (±1.06)

1.79 (±1.63)

0
1/704 =0.14%a

0.0692

Total

32
109/704 = 15%a

microRNAs
miR-374

2.05 (±2.03)

1.12 (±0.99)

Comparison of Total Number of miRNAs Not Expressed by the Two Methods a
*

0.0006
0.0340
0.8240
0.2461

<0.0001
<0.0001

|ΔΔCT|= Absolute Value [Operator 1 ΔCT – Operator 2 ΔCT].
Bold = statistically significant. a = chi-squared test comparing number of miRNA not expressed using Trizol LS with preamplification as compared to using
Qiagen miRNeasy without preamplification
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Trizol LS with Preamplification
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Figure 5. Heat map showing expression of 11 miRNA in plasma of 16 patients with colorectal adenoma prior to treatment and
in plasma of 16 controls

7. SETTING OF CYCLE THRESHOLD
In order to compare cycle threshold (CT) values across plates, both fixed and
variable thresholds were utilized. Since different miRNAs on the same plate may have
different linear phases, a fixed threshold may not intersect across the linear phase. For
this reason, the variable threshold is the default setting. The relative quantitation (RQ)
manager from Applied Biosystems may use a different threshold (variable) within the
same plate if one selects the option “automatic CT”. Different thresholds will be chosen
for different miRNAs according to the linear phases. However, these CT values cannot
be compared directly between different plates. The threshold needs to be considered in
the analysis and adjustment of the CT values, if needed. In addition to this variable
threshold setting, we examined the effect of fixed threshold settings of 0.01, 0.03, 0.05,
or 0.5. CT values, threshold, and 40 cycles fluorescence intensities are miRNA-rated
from RQ manager 1.2, Applied Biosystems.
Setting the cycle threshold bar at a fixed value of 0.03 was preferable to using the
default “variable” threshold setting, provided that the number of missing values was less
than 10%. Using the modified phenol/guanidine-based lysis and silica membrane-based
extraction technique (mirNeasy), only 0.14% of values were missing. With this method
of extraction, therefore, utilization of a fixed threshold of 0.03 yields reproducible results
without the need for normalization required with the use of a variable threshold.

8. INTRA-OPERATOR VARIABILITY
Assays for individual miRNA for each patient sample were run in duplicate to
permit assessment of intra-operator variability (comparison of duplicate samples).
32

There was no significant variability between duplicate samples performed by a
single operator (Table 8). A paired t-test among duplicate samples was used to assess
statistical significance.
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Table 8. Intra-Operator Variability (Duplicates) for the Trizol LS RNA Extraction and Preamplicification Protocol

p-value
0.9518
0.6177
0.4240
0.6186
0.3265
0.2216

miR-520d5p
miR-122

35.61 (±1.90)

35.24 (±1.77)

0.36

28.88 (±2.40)

29.11 (±2.82)

0.23

0.6814

miR-485-3p

29.32 (±3.06)

29.44 (±3.32)

0.12

0.8320

miR-21

26.97 (±2.58)

26.96 (±2.81)

0.01

0.9833

miR-218

35.90 (±2.38)

35.83 (±2.08)

0.07

0.9206

†

0.4806

|ΔCT| = absolute value (mean cycle threshold value for duplicate 1 for the miRNA of interest – mean cycle threshold value for duplicate 2 for the
miRNA of interest.
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Colorectal Advanced Adenoma (n=16) + Control (n=16)
Mean CT Value
Mean CT Value
microRNAs
Duplicate B
|ΔCT|†
Duplicate A (±SD)
(±SD)
miR-374
25.98 (±1.80)
26.00 (±1.93)
0.02
miR-142-3p
28.48 (±2.77)
28.74 (±3.05)
0.27
miR-523
20.48 (±2.08)
20.21 (±1.71)
0.27
miR-374-5p
29.47 (±3.53)
29.81 (±3.61)
0.34
miR-376c
32.27 (±2.63)
31.68 (±2.33)
0.58
miR-27a
28.62 (±2.25)
29.24 (±2.99)
0.62

9. INTER-OPERATOR VARIABILITY
In order to assess inter-operator variation following total RNA extraction, two
experienced operators separately performed subsequent sample processing, including
reverse transcription, preamplification (for samples extracted using TRIzol LS), and
qPCR. Each operator used the same thermocycler (Mastercycler, Eppendorf, Hamburg,
Germany) and Step-One Plus RT-PCR System, but at different times on different days.
The cycle threshold (CT ) values were exported with the CT bar set at 0.03.
Inter-operator variability was assessed using two different miRNA extraction
techniques. Inter-operator variability using the Trizol LS purification and preamplification showed one miRNA miR-21 to be significantly different between
operators. In addition, a large number of samples were noted to have no miRNA
expression for 6 of the 11 evaluated miRNA (Table 9). The large number of samples with
no miRNA expression again highlighted the importance of selecting the best extraction
technique, since this was not seen with the other method (see also data Table 7). Interoperator variability using the Qiagen miRNeasy technique yielded 2 miRNAs (miR-4853p and miR-21) with statistically significantly different ∆CT values (p-values comparing
the ∆CT of the two different operators, 0.0191 and 0.0500, respectively) (Table 10). It
was believed that these differences in miRNA expression data between operators were
within the range of experimental error. Indeed, when these experiments were repeated,
these differences were not observed (data not shown). In order to determine whether any
inter-observer differences would have a significant impact upon observed group
differences we utilized an ANOVA model to examine variations in both miR-21 and
RNU6. The group effect remained significant, even when there was an effect of inter35

operator variability. The coefficient of variation for RNU6 was 9.1398, and 8.1211 for
miR-21. In addition, we determined the mean and standard deviation of 64 measurements
of miR-21 performed in plasma samples of patients with adenoma (mean 26.3 ± 1.8 ,
median 25.9) as well as 64 measurements of miR-21 performed in plasma samples of
controls (mean 27.6 ± 3.2, median 28.4).
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Table 9. Differences in ΔCT between operators with Trizol LS RNA extraction and pre-amplification (inter-operator variability).

miR-374
miR-142-3p
miR-523
miR-374-5p
miR-376c
miR-27a
miR-520d5p
miR-122
miR-485-3p
miR-21
miR-218

†

8.57 (±3.39)

14

7.00 (±2.73)

17

0.1587

2.41 (±4.23)
1.48 (±2.35)
-1.83 (±2.60)
8.01 (±2.88)

5
0
0
13

2.21 (±3.98)
1.34 (±2.50)
0.05 (±2.01)
8.93 (±2.62)

8
0
0
19

0.8632
0.8182
0.0019
0.3650
Total
Average

ΔCT = miRNA of interest cycle threshold value - U6 cycle threshold value.
|ΔΔCT|= Absolute Value [Operator 1 ΔCT – Operator 2 ΔCT].
¥ = p value of mean ΔCT operator 1 vs operator 2.
Bold = statistically significant.
*

Mean
|ΔΔCT|*(±SD)

1.69 (±1.32)
1.69 (±1.83)
1.45 (±1.45)
1.69 (±1.73)
2.42 (±1.42)
1.29 (±1.23)
2.05 (±2.03)
1.82 (±1.86)
1.45 (±1.45)
2.40 (±1.82)
1.77 (±1.79)
1.79 (±1.63)
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microRNAs

Colorectal Advanced Adenoma (n=16) + Control (n=16)
Unpaired t-test - Cycle Threshold = 0.03
Operator 1
Operator 2
p# miRNA
Mean ΔCT†
# miRNA
Mean ΔCT†
¥
Not
value
(±SD)
Not Expressed
(±SD)
Expressed
-1.95 (±2.53)
0
-1.53 (±2.39)
0
0.4974
0.84 (±1.99)
0
1.23 (±3.06)
0
0.5478
-7.01 (±3.11)
0
-7.78 (±2.17)
0
0.2551
2.02 (±2.59)
2
2.83 (±2.85)
3
0.2577
5.83 (±2.21)
11
5.48 (±2.71)
11
0.6490
1.25 (±1.46)
1
1.50 (±1.77)
5
0.5580

Table 10. Differences in ΔCT between operators with Qiagen miRNeasy with RNA Carrier and No Pre-amplification (InterOperator Variability).

miR-374
miR-142-3p
miR-523
miR-374-5p
miR-376c
miR-27a
miR-520d5p
miR-122
miR-485-3p
miR-21
miR-218
†

0.70 (±0.78)
0.91 (±0.89)
1.38 (±1.02)
1.27 (±1.06)
0.76 (±0.91)
0.98 (±1.03)

5.54 (±2.54)

0

6.27 (±2.91)

1

0.2925

1.20 (±1.01)

-2.69 (±2.96)
-2.60 (±2.02)
-7.59 (±1.75)
-3.73 (±2.28)

0
0
0
0

-2.05 (±3.58)
-1.31 (±2.26)
-6.69 (±1.85)
-2.90 (±2.23)

0
0
0
0

0.4387

1.11 (±1.10)
1.50 (±1.01)
1.36 (±1.00)
1.09 (±1.06)

ΔCT = miRNA of interest cycle threshold value - U6 cycle threshold value.
|ΔΔCT|= Absolute Value [Operator 1 ΔCT – Operator 2 ΔCT].
¥ = p value of mean ΔCT operator 1 vs operator 2. Bold = statistically significant
*

Mean
|ΔΔCT|*(±SD)

0.0191
0.0500
0.1460
Total
Average

1.12 (±0.99)
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microRNAs

Colorectal Advanced Adenoma (n=16) + Control (n=16)
Unpaired t-test - Cycle Threshold = 0.03
Operator 1
Operator 2
p# miRNA
Mean ΔCT†
# miRNA
Mean ΔCT†
Not
value¥
(±SD)
Not Expressed
(±SD)
Expressed
-1.80 (±1.75)
0
-1.69 (±1.99)
0
0.8151
-7.16 (±1.57)
0
-6.60 (±1.81)
0
0.1910
-3.21 (±2.82)
0
-2.12 (±2.92)
0
0.1339
-3.27 (±1.94)
0
-2.33 (±1.87)
0
0.0529
-0.04 (±1.74)
0
0.05 (±1.98)
0
0.8475
-6.12 (±1.56)
0
-5.52 (±1.79)
0
0.1579

10. SELECTION OF HOUSEKEEPING GENE (HKG)
We determined expression of the following housekeeping genes (HKGs): Let-7a,
Let-7d, Let-7g, miR-16, RNU6, RNU48, miR-191, miR-223, miR-484, and miR-520d5p. The cycle threshold (CT) was fixed at 0.03 for all samples. Once RT-PCR was
performed for all samples, for each potential HKG, the mean CT and standard deviation
was calculated for all sample groups, allowing for comparison among HKGs.95
Following identification of the HKGs with uniform expression in all samples, and
the narrowest standard deviation, we then used these HKGs alone or in combination as
reference to determine their utility in comparing differences in miRNA expression
between groups. Only miRNA which were expressed in ≥ 50% of subjects in each groups
were analyzed.
The number of samples in which these HKGs were expressed by patient groups is
shown in Table 11. Let-7a, Let-7d, Let-7g, and RNU48 were only expressed in 26%, 7%,
10%, and 8% of these samples, respectively. Only miRNAs with uniform expression in
all samples were included in the subsequent analysis.
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Table 11. Percentage of Housekeeping Gene (HGK) Samples Expressed within Each Group Investigated.

Patient Groups (Number and Percent of Samples Expressing HKG)
Colorectal
Adenoma
n=11
9 (82)

Breast Cancer
n=10

Lung Cancer
n=10

Let-7a

Colorectal
Cancer
n=20
17 (85)

Control
n=12

6 (60)

Pancreatic
Cancer
n=10
7 (70)

9 (90)

Let-7d

19 (95)

10 (91)

10 (100)

7 (70)

10 (100)

12 (100)

Let-7g

19 (95)

9 (82)

10 (100)

8 (80)

9 (90)

12 (100)

RNU48

19 (95)

11 (100)

10 (100)

8 (80)

7 (70)

12 (100)

miR-16

20 (100)

11 (100)

10 (100)

10 (100)

10 (100)

12 (100)

mir-191-5p

20 (100)

11 (100)

10 (100)

10 (100)

10 (100)

12 (100)

miR-223

20 (100)

11 (100)

10 (100)

10 (100)

10 (100)

12 (100)

miR-484

20 (100)

11 (100)

10 (100)

10 (100)

10 (100)

12 (100)

miR-520d-5p

20 (100)

11 (100)

10 (100)

10 (100)

10 (100)

12 (100)

RNU6

20 (100)

11 (100)

10 (100)

10 (100)

10 (100)

12 (100)

Shaded areas indicate all samples expressing HKG of interest

6 (50)
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HGKGene
(HKG)

RNU6, miR-520d-5p, miR-16, miR-191, miR-223, and miR-484 were expressed
in all samples. The mean CT and standard deviation for each of these remaining 6
potential HKGs that were expressed in all samples are listed in Table 1. Figure 1 is an
example of PCR output showing CT values of HKG U6 and miR-520d-5p. RNU6, a
commonly used HKG, was consistently expressed in all samples with a narrow standard
deviation (Table 12).
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Table 12. Mean and Standard Deviation of Housekeeping Genes with 100% expression.

RNU6*

miR-16

miR-191

miR-223

miR-484

miR-520d-5p*

Colorectal Cancer (n=20)

22.4 +/- 3.8

19.4 +/- 4.7

18.4 +/- 4.5

15.0 +/- 4.2

15.6 +/- 2.8

29.5 +/- 0.8

Breast Cancer (n=10)

25.8 +/- 3.2

20.8 +/- 4.4

19.3 +/- 4.5

16.1 +/- 4.4

17.4 +/- 3.7

29.7 +/- 1.3

Lung Cancer (n=10)

26.8 +/- 2.4

22.6 +/- 4.6

22.2 +/- 4.6

19.3 +/- 4.7

19.7 +/- 4.3

29.0 +/- 0.6

Pancreatic Cancer (n=10)

27.3 +/- 2.2

25.2 +/- 2.1

21.3 +/- 4.7

19.8 +/- 3.2

17.8 +/- 3.1

30.4 +/- 0.8

Colorectal Adenoma (n=11)

22.6 +/- 2.5

20.2 +/- 3.7

18.0 +/- 3.0

14.7 +/- 3.0

15.0 +/- 1.6

30.7 +/- 0.9

Comparison (n=12)

22.0 +/- 2.2

21.2 +/- 1.8

20.1 +/- 2.7

17.5 +/- 2.7

17.2 +/- 1.6

30.5 +/- 1.0

* Data for RNU6 and miR520d-5p shown in shaded areas showed the narrowest standard deviation, with least variability between groups
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Mean CT (+/- Standard Deviation)

In addition, our data indicated that a gene that has not been previously reported as
an HKG (miR-520d-5p) had a remarkably stable expression over a variety of samples. Of
all the HKGs we investigated, miR-520d-5p exhibited the narrowest range of expression
(29.0-30.7) and the smallest standard deviation among samples as well as being
expressed in all samples. Although we could find no reports describing use of miR-520d5p as an HKG, due to the reliable expression and narrow standard deviation, we suggest
that it could be used reliably in plasma miRNA research.
miRNA expression data using both HKG’s (RNU6 and miR-520d-5p) with the
highest expression and narrowest standard deviation are shown in table 13. Overall use of
RNU6 seems generally to be superior to using either miR520d-5p alone or the average of
RNU6 and miR520d-5p; however because of greater variability within the same sample
with RNU6, we would recommend using a combination of RNU6 and miR520d-5p.
RNU6 has a higher expression than miR520d-5p. HKG with different expression than the
miRNA of interest is recommended. Sample size does appear to play a role. For example
in our comparison of controls vs all other groups, or in the comparison of CRC vs CRAd
our sample sizes are small and/or unequal (unbalanced). In this scenario results are less
clear, than where sample sizes are more equal and where results are more consistent
between RNU6, miR520d-5p and the combination of the two. 99, 102-107
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Comparator
Groups

Control vs All Others*
RNU6
520d-5p
RNU6 & miR520d5p
(CRC & Crad) vs
(BC,LC,PC)
RNU6
520d-5p
RNU6 & miR520d5p
CRC vs Crad
RNU6
520d-5p
RNU6 & miR520d5p

No. miRNA
Expressed in
>50% of
samples in
each group

No. miRNA
with raw
p<0.05

No. miRNA
with FDR
adjusted
p<0.25

No. miRNA
with FDR
adjusted
p<0.1

No. miRNA
with AUC
>0.7

No. miRNA
present in all
samples in all
groups

No. miRNA
with FDR
adjusted p<0.1
AND present
in >80 of
samples in
both groups

173
173
173

147
0
63

164
0
117

156
0
26

156
5
82

26
26
27

102
0
9

219
176
176

107
110
40

138
141
45

114
120
28

82
80
29

27
27
27

58
82
19

219
219
219

2
1
3

2
1
1

2
1
1

8
17
11

43
43
43

1
0
0

* All others includes colorectal cancer (CRC), colorectal adenoma (Crad), breast cancer (BC), lung cancer (LC), and pancreatic cancer
(PC)
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Table 13. Expression data for Housekeeping Genes RNU6 and miR520d-5p

11. DISCUSSION
With the growing field of miRNA research and the potential use of miRNAs as
biomarkers for cancer and other human diseases, the lack of standardization and
reproducibility among studies is becoming more apparent. Such variations in
methodology can lead to large variability in results reported from one research group to
another. Six different sources of variation in experimental technique were examined with
respect to their effect on miRNA expression data: 1) time of plasma extraction, 2) method
of RNA extraction, 3) cycle threshold setting, 4) intra-operator variability 5) interoperator variability and 6) selection of housekeeping gene. Our brief literature review of
a 1-year time frame, was not meant to be an exhaustive review, but rather to provide a
“snap-shot” of current practices of performing experiments and analyzing data. Our
literature review has shown, that many publications focusing on plasma miRNA do not
carefully describe their experimental methods, that there is wide variation in performing
such studies and analyzing resulting data.
There has been discussion as to whether plasma or serum is better for study of
circulating miRNA. While some report comparable data others report differences
between the two sources 108-110. We chose to focus on plasma, due to the concerns that
miRNAs might be released from blood cells into the serum during the coagulation
process as suggested by Wang et al 109.
Our data regarding the timing of plasma extraction suggest that plasma needs to
be isolated rapidly, within hours after phlebotomy. With blood samples that were stored
at 4˚C, even with a modest sample size, we observed statistically significant different
∆CTs for select miRNA beginning as early as plasma extraction at 24 h. This is in
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agreement with prior reports linking hemolysis to altered miRNA expression 111. Due to
the limited sample size and small number of miRNA investigated, we suggest that plasma
be isolated within 12 h following phlebotomy in order to avoid falsely elevated or
reduced miRNA expression levels.
The three most widely used methods of total RNA extraction from plasma or
serum are guanidinium thiocyanate-phenol chloroform-based methods (e.g., Trizol LS,
Life Technologies, Carlsbad, CA), phenol with glass fiber filter-based (e.g. miRVANA,
Ambion®, Life Technologies), and phenol/guanidine with silica membrane based
purification (e.g. miRNeasy, Qiagen, Venlo, The Netherlands). Moret et al. 101 compared
all three methods and found that a modified phenol/guanidine lysis with silica membranebased RNA extraction method yielded enhanced quantity, purity, and performance on
assays. Although we did not assess the glass-fiber filter-based method here, our data
agree with those of Moret et al. 101 and suggest that the Qiagen miRNeasy with yeast
carrier isolation method yields a very reproducible result. The high concentration of 353
+/- 85 ng/µL total RNA obtained with this technique as compared to Trizol LS, which
resulted in concentration of 19 +/- 12 ng/µL, allows for pre-amplification to be omitted
prior to qPCR, omitting yet another source of data variability. In using this technique, we
were able to reduce the number of “missing” samples (miRNA that did not express) from
15% to 0.14%.
Analysis of various fixed as well as of variable threshold settings indicated that a
fixed Ct setting of 0.03 produced the most reproducible data provided that < 10% of data
were missing. This has the significant advantage of not requiring the additional statistical
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adjustment that is required when a variable threshold is utilized (Rai et al., unpublished
data, 2014).
We demonstrated a lack of significant intra-operator variability. In view of this,
triplicates are not necessary, and if there are few missing values (<10%), one could even
question the need to perform duplicates given the very low ∆∆CT. Inter-operator
variation was also low. Using the phenol/guanidine-based lysis and silica membranebased purification technique resulted in a narrowing of ∆∆CT values between operators
as compared to guanidinium thiocyanate-phenol chloroform purification. In fact, when
these experiments were repeated, the differences in miRNA expression between operators
for miR-21 and miR-485-3p were not seen, leading us to conclude that this was within
the range of experimental error and not a significant issue.
When determining CT values and normalizing miRNA expression of samples of
interest to an internal HKG, it is imperative that the HKG be reproducible and express at
similar values across all samples. An ideal HKG should meet the following criteria: 1)
Expressed in all samples, 2) Have medium-to-high levels of expression in the specimens
analyzed and 3) Have consistent levels of expression with narrow standard deviation.
When applying these three criteria to our data, Let-7a, Let-7d, Let-7g and RNU48 were
eliminated since they were not expressed in all samples. Of the 6 remaining potential
HKGs, two had a very narrow standard deviation as well as consistent expression: RNU6
and miR-520d-5p. Based upon our data, due to the narrow standard deviation and less
variability among groups, we propose that both RNU6 and miR520d-5p should be used
as HKGs.
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Based upon our studies, rapid plasma extraction is essential. A modified
phenol/guanidine-based lysis and silica membrane-based purification RNA extraction is
preferred due to the extremely low rate of missing values and high RNA yield, allowing
the investigator to avoid using pre-amplification, another source of variability. If there is
a low number of missing values (<10 %), a fixed threshold setting of 0.03 provides the
most reliable, consistent data without the need for data normalization. With this setting,
there is no significant intra-operator variability, i.e. replicates can be restricted to
duplicates, rather than triplicates, resulting in cost and labor savings. RNU6 and miR520d-5p are the most reliable of the 10 studied HKGs for studies of plasma miRNA. The
use of plasma miRNA as biomarkers of human disease is evolving and expanding. Data
reproducibility is essential prior to clinical application. Standardization of analytic
methods and reporting is necessary to permit accurate data comparison and validation.

A.

COLON CANCER CELL LINES USED TO DETECT MIRNA DIFFERENCES
BETWEEN CANCERS OF DIFFERING GROWTH RATES AND
METASTATIC CAPABILITY

The Price Institute at The University of Louisville allows for a unique situation to study
tissue and plasma samples on patients that are followed clinically by the lead investigator.
This gives a large range of pathology, but has limitations due to heterogeneity among
patients with respect to preoperative treatment, race, gender, immune factors and other
variables. Studies using commercially available colon cancer cell lines offer several
advantages. First and foremost is the reproducibility of cell lines. When minimizing the
pass rate (the amount of times the cells are divided), early passes of cell lines behave
nearly the same within that cell line across different experiments. This is important when
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dealing with cancer cells that tend to divide rapidly and already behave differently than
non-cancerous cells. With meticulous study and observation, after a few weeks, we know
the behavior of the different cell lines under investigation. This is important because once
their “normal” growth rate and behavior is known; it allows us to use external means to
manipulate these cells to study different states to which cancer cells could possibly be
exposed to in a patient. Although use of such cell lines is widely accepted they do have
disadvantages. Cell lines are immortalized cancer cells. No matter what the conditions
are; this will add caution to interpreting the results until these results are in turn tested in
animal models or verified in a human clinical trial.
Not only do cell lines allow us to manipulate cancer pathology to investigate
different aspects of cancer pathway progression, buy they also allow us to study these
pathways in different stages of cancer. By utilizing well established immortalized CRC
cell lines, we can examine different cancer stages. It allows us to look at benign noncancerous epithelial cell lines as well as cancer cell lines.
Prior to developing a hypothesis, screening arrays were performed utilizing TaqMan® microfluidic technology array cards. In this screening, the overall goal was to
establish which miRNAs were differentially dysregulated between cell lines of different
cancer stages. The use of both an “A” card and “B” card was utilized, each assessing 384
unique human miRNA (760 total miRNAs). Dukes A-D cell lines were screened and had
a high number of these miRNAs expressed in each cell line (Table 14). Of the miRNAs
expressed miRNA-99a and miRNA-100 had a unique expression that no other set of
miRNAs had (Table 15). This differential expression led us to further investigate
miRNA-99 and miRNA-100.
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Not to our surprise an extensive amount has been published regarding the
miRNA-99 family, which includes miRNA-99a, -99b and -100. Specifically, a large
amount of work has been done investigating the role of the miRNA 99 family and its
suppression of prostate-specific antigen and cancer proliferation in prostate cancer.112 We
investigated different pathways with which the miRNA 99 family was associated and
noted its involvement in the mammalian target of rapamycin (mTOR) pathway. Although
some work has been done previously with respect to the role of mTOR in colorectal
cancer, there are few reports examining the effect of miRNA-99a mTOR protein
expression and its ultimate effect on downstream targets of the mTOR pathway.
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Table 14. Number of miRNAs expressed in screening array of cell lines ranging from
Dukes A-Dukes D.

Number of miRNAs Expressed
Duke’s A Duke’s B Duke’s C Duke’s D

TLDA Card (SW1116) (SW480) (HT-29) (HCT116)
1st 384
293
335
314
313
microRNAs
2nd 384
262
219
209
210
microRNAs
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Table 15. Fold Change and Regulation of miRNA 99 Family in the screening array for
colorectal cancer cell lines.

Fold Change
microRNAs
miR-100
miR-99a

Fold Regulation

Dukes' Dukes' Dukes' Dukes' Dukes' Dukes' Dukes' Dukes'
A vs.
B vs.
C vs.
D vs.
A vs.
B vs.
C vs.
D vs.
Control Control Control Control Control Control Control Control
0.03
0.14
0.02
4.91
-39.5
-7.1
-52.3
4.9
0.02
0.14
0.03
4.85
-45.4
-7.0
-34.2
4.8
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CHAPTER III
MAMMALIAN TARGET OF RAPAMYCIN (MTOR) SIGNALING PATHWAY
miRNAs have been shown to be involved in multiple pathways in all types of
cancers; this is no different with colorectal cancer. One of the pathways that have been
shown to influence cancer behavior, especially in prostate cancer, is the mTOR signaling
pathway. Although much is known about this pathway and its two protein complexes,
mTORC1 and mTORC2, there is still much to learn in regards to its relationships to CRC
and its influence on CRC progression.
Over the past several decades the mTOR, which is now referred to as the
mechanistic target of rapamycin, mTOR signaling pathway (Figure 6) has been shown to
play an integral role in the regulation of organ growth and homeostasis. Due to its
regulation of multiple cellular processes, it has been shown to influence multiple cancer
pathways, obesity and type 2 diabetes to name a few. This has led to much interest in
further understanding this pathway in various disease states and particularly interest with
respect to potential for pharmaceutical intervention in the mTOR pathway.
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Figure 6. mTOR pathway

Mathieu Laplante, and David M. Sabatini Cold Spring Harb Perspect Biol
2012;4:a011593
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TOR1 and TOR2 genes were identified in the early 1990s during genetic
screening in budding yeast. These were shown to be mediators of the toxic effects of
rapamycin on yeast. Rapamycin is a naturally occurring macrolide produced by
Streptomyces hygroscopius bacteria. mTOR itself is a serine/threonine protein kinase that
is part of the phosphoinositide 3-kinase (PI3K)-related kinase family and interacts with
several proteins to form two distinct complexes aptly named mTOR complex 1(mTOR
C1) and complex 2 (mTORC2). Not yet completely understood, the mechanism of action
of rapamycins effect on mTOR is thought to occur by a gain-of-function complex when
rapamycin binds intracellularly with the 12-kDA FK506-binding protein. It is believed
that this rapamycin-FK506 complex will then interact with and inhibit mTOR protein
when a part of the mTORC1 complex but does not inhibit the function of mTOR when it
is a part of mTORC2. Although rapamycin-FK506 is implicated in this inhibition
process, the exact binding process of this complex to mTORC1 has yet to be discovered.
A.

MTOR COMPLEX 1 (MTORC1)

mTORC1 is composed of six protein components:
1. mTOR protein
2. mammalian lethal with sec-13 (mLST8, also called GBL)
3. DEP domain containing mTOR-interacting protein (DEPTOR)
4. Tti1/Tel2 complex
5. Regulatory-associated protein of mammalian target of rapamycin (RAPTOR)
6. proline-rich Akt substrate 40kDa (PRAS40)
RAPTOR and PRAS40 are the two proteins that are unique to mTORC1, and are not a
part of mTORC2.
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mTORC1 is involved in multiple key processes needed for health, not limited to
but including protein synthesis, autophagy and lipid synthesis. This complex helps
regulate downstream proteins that are key in protein synthesis. One of these being the
eukaryotic initiation factor 4E (eIF4E)-binding protein 1 and the p70 ribosomal s6 Kinase
1 (S6K1). Previously described, the phosphorylation of 4E-BP1 inhibits its binding to
eIF4E, which then in turn promotes cap-dependent translation. In addition S6K1 is
stimulated by mTORC1 and leads to its involvement in mRNA development, capdependent translation and regulation of many other protein activities.
Apropos autophagy, which is the degradation of cellular components by lysosomes,
mTORC1 increases autophagy when it is inhibited. The opposite is true also, as when
mTORC1 is stimulated by upstream inputs autophagy will decrease. This suggests that
inhibition of TORC1 can lead to unregulated cell growth.
B.

MTOR COMPLEX 2 (MTORC2)

mTORC2 is composed of seven protein components:
1. mTOR protein
2. mLST8
3. DEPTOR
4. Tti1/Tel2 complex
5. Rapamycin-insensitive companion of mTOR (RICTOR)
6. Mammalian stress-activated map kinase-interacting protein 1 (mSin 1)
7. Protein observed with rictor 1 and 2 (protor 1/2)
RICTOR, mSin1 and protor 1/2 are the 3 unique proteins that are a part of mTORC2.

C.

REGULATORS OF MTORC1
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mTORC1 has multiple inputs from various upstream pathways. These currently
include but are not limited to, growth factors, stress, energy status, oxygen availability
and amino acids. These inputs lead to mTORC1's control on protein/lipid synthesis and
autophagy.
mTORC1 is regulated by growth factors that initially increase the phosphorylation
of TSC2 via the protein kinase B (PKB) activation cascade. The activation of TSC2 in
turn leads to inactivation of mTORC1. In addition extracellular-signal-regulated Kinase
1/2 and S6K1 have the opposite effect and inhibit or deactivate the TSC1/2 complex that
in turn leads to activation of TORC1.
D.

REGULATORS OF MTORC2
Compared to mTORC1, all aspects of the mTORC2 pathway, including its

regulators are less well understood. Due to the inability of FKBP-12-rapamycin to bind to
the intact mTORC2, it was originally thought that this complex was completely
insensitive to rapamycin, however, recently it has come to light that this is not the
case.113 The complex nature of mTORC2 is shown by the fact that some cells over time
reduce mTORC2 signaling via suppression of mTORC2 assembly, by an as yet not
understood mechanism.113 Unlike mTORC1, mTORC2 is insensitive to upstream
nutrients, yet responds to certain growth factors, including insulin. The mechanism of this
is currently not known, but ribosomes are known to be necessary for this signaling to
occur.113
One facet of mTORC2 activity that is known is its effect upon AKT, which helps
regulate certain cellular processes such as metabolism, growth, proliferation, metabolism
and cellular survival. Sarbassov et al, in 2005 showed that mTORC2 phosphorylates
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AKT at its hydrophobic motif, which results in its activation.114 In addition, it has been
shown that silencing components of mTORC2 impairs the phosphorylation of some
targets of AKT, whereas other targets of AKT are unaffected.115, 116
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CHAPTER IV
HYPOTHESIS AND SPECIFIC AIMS
Several pathways that influence colorectal cancer have been shown to interact
with the mTOR pathway such as the wnt pathway, PI3/AKT, P53 and RAS/RAF. These
pathways influence normal cell life progression including apoptosis, tumor suppression,
protein activation and cell binding to name only a few of their functions. Although
mTOR has been shown to influence colorectal cancer, the link between the miRNA 99
family and mTORs and its influence on CRC is not clear. It has been shown that certain
miRNAs bind to mTOR, however, changes in the cells’ activity, and downstream protein
expression have not yet been fully described.
Preliminary work in our laboratory has shown the miRNA 99 family miRNA to
be differentially expressed among colon cancer cell lines of different metastatic potential,
suggesting that these miRNA may play a role in invasiveness and metastasis in CRC.
This was investigated with the following hypothesis:
Hypothesis: miR-99a decreases cell proliferation, migration and possibly invasion
of colorectal cancer cell lines by decreasing mTORC1 and mTORC2
expression.
3 Specific Aims will be investigated:
1.

To determine the effect of miRNA-99a on mTOR protein phosphorylation
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2.

To determine miRNA-99a’s influence on the phosphorylation of mTOR
pathway’s downstream proteins: S6K1and 4EBP1

3.

To determine if transfection of HT-29, HCT-116 and CCD841 cell lines with
miRNA-99a will inhibit cell migration and invasion
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CHAPTER V
MATERIALS AND METHODS:
A.

CELL LINES
In this study, three relevant cell lines (Table 1) acquired from American Type

Culture Collection (ATCC, Manassas, Virginia) were reinitialized from frozen (-80°C)
material, then either allowed to grow for future testing, i.e. Western blot analysis,
polymerase chain reactions (PCR) or immunohistochemistry (IHC), or grown for
harvesting to be used at a later time. All cell lines were adhesive in nature and are not
free floating cell lines, i.e. when cells are growing and dividing they adhere to the cell
culture flasks.
1. CCD 841 CoN (ATCC® CRL-1790™)
Normal epithelial colon cells were harvested from a human female fetus at the 21
week gestation period and cultured in Eagle’s Minimum Essential Medium
(EMEM) supplemented with 0.5% mixture of penicillin, streptomycin,
amphotericin B, 0.5% L-glutamine, and 10% Fetal Bovine Serum (FBS).
2. HT-29 (ATCC® HTB-38™)
Dukes’ type C primary colorectal adenocarcinoma epithelial cells were harvested
from a 44 year-old woman and cultured in McCoy’s 5A medium supplemented
with 0.5% mixture of penicillin, streptomycin, amphotericin B, 0.5% Lglutamine, and 5% FBS.
3. HCT-116 (ATCC® CCL-247™)
Dukes’ type D, primary colorectal carcinoma epithelial cells were harvested from
a man (age not stated), and cultured in McCoy’s 5A medium supplemented with
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0.5% mixture of penicillin, streptomycin, amphotericin B, 0.5% L-glutamine, and
5% FBS. Notably it has come to light that this cell line is not a typical
adenocarcinoma Dukes’ D cell line but from a patient with Hereditary
Nonpolyposis Colorectal Cancer (HNPCC), which is a type of cancer that is
defective in DNA mismatch repair, which will lead to microsatellite instability.
Depending on the sub-classification of HNPCC, there have been up to 7 different
genes implicated.117-122
B.

MAINTENANCE OF CELL LINES
Each cell line was maintained in a cell culture hood, which was swabbed down

with 70% ethanol (EtOH) before and after each use and the hood was run for 10 minutes
prior to working to establish protective air flow. All items, including gloved hands,
entered the hood only after being cleansed with 70% EtOH. Only one cell line and
appropriate culture medium were placed in the cell culture hood at any given time and the
hood was cleaned with 70% EtOH in between cell line transfers.
1. INITIAL CULTURING OF CELLS
For each cell line, 8mL of appropriate culture media was first added to a 15mL
tube. Then 9mL of appropriate culture media was added to a 25 mL cell culture flask.
The flask was incubated to allow temperature equilibration of the culture media prior to
placing the freshly thawed cells into the flask. The vial of frozen cells was then rapidly
thawed in a 37°C water bath, keeping the O-ring and cap out of the water to reduce
contamination. After the cells were thawed, the external surface of each vial was cleansed
with 70% EtOH, placed in the hood and transferred to the 15mL tube with appropriate
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culture media. Finally, the flask with the thawed cells is rinsed using 1 mL of appropriate
culture media and added to the 15 mL tube. The contents of the 15mL tube were
centrifuged at 125g, at 37°C for 6 minutes, until a cell pellet was formed. The cell pellet
was aspirated and then resuspended using 1mL of appropriate culture media via a
micropipette tip to obtain cell suspension. The cells were then added to the pre-warmed
25 mL flask with 9 mL of appropriate culture media which was gently rocked in order to
disperse cells and then was placed back in the incubator at 37°C, where they were left to
grow with daily monitoring.
2. SUB-CULTURING/SPLITTING CELLS
Prior to sub-culturing or splitting cell lines, the current flask of actively growing
cell lines was viewed at 10x magnification to determine whether the cells were 70-90%
confluent and ready to be divided. When the cells were determined to be proper
confluent, they were then transferred from the incubator into the cell culture hood. For
each cell line the appropriate culture media and a 3 mL aliquot of trypsin-EDTA were
then set into a 37°C water bath to thaw. Once thawed, the 15 mL tube of trypsin-EDTA
and bottle of cell culture medium were vortexed and homogenized, then the containers
were cleaned with 70% EtOH and placed in the cell culture hood. With the culture flask
inside the cell culture hood, the next step was to remove the old culture medium from the
flask and discard it into the waste beaker. The flask was then washed with 0.5mL of
trypsin for 2-3 seconds and then emptied into the waste beaker. Next, 2.5 mL of trypsin
was added to the flask, gently rocked and the flasks were observed through an inverted
microscope to determine when the cells had rounded up into the trypsin media off the
bottom of the flask. The type of cell line, as well as confluence of the cells, has an effect
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on how fast the trypsin works. While the trypsin acted on the old culture flask, the
appropriate cell culture medium was added to a new 75 mL flask(s) and incubated at
37°C. Once the trypsin exerts its effect, the cells are rounded up and suspended; 8mL of
appropriate culture media was added to the flask. This cell suspension was added to a
15mL tube and then centrifuged at 125g, at 37°C for 6 minutes, until a new cell pellet
was formed. This 15mL tube was then cleaned with 70% EtOH and placed back into the
cell culture hood. The supernatant was discarded and the cell pellet was re-suspended
using 1mL of appropriate culture media via a micropipette tip to obtain a single-cell
suspension.
At this point, cells were counted using a hemocytometer for further experiments
or divided in pre-determined ratios for sub-cultivation. The split ratios for each cell line
are detailed in Table 16.
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Table 16. Cell line criteria for each passage
Cell Line:

Subcultivation* Ratio: Medium Renewal per Number of cells
week:

per 75mL flask:

CCD841
Normal
fetal

1:2 – 1:3

2-3 times

2 x 106

HT29
Dukes C

1:3 – 1:8

2-3 times

≥1-2 x 106

HCT116
Dukes D

1:3 – 1:10

2-3 times

≥1-2 x 106

*Sub-cultivation refers to the multiple passes or generations of each cell line.

65

The calculated amount of cells was then added to the new 75 mL flask with prewarmed (37°C) culture media. Finally, the flask with cells in suspension was labeled with
cell line name, passage number and date, then gently rocked and returned to the
incubator.
3. SUBSEQUENT FREEZING OF CELLS
The appropriate cryo-medium was created by taking a cell lines’ respective
medium and adding 5% sterile dimethyl sulfoxide (DMSO) to the final concentration.
Similar to the sub-culturing/splitting protocol, the cells were treated with trypsin-EDTA,
collected in media, and the cell suspension centrifuged into a pellet. However, as opposed
to re-suspending the cell pellet in normal cell culture media, cryo-media was used. The
cells were counted and the concentration of cells was adjusted to 4 x 106 cells/2mL of
cryo-media. 2mL of the suspension was added to cryo-flasks that were specifically
labeled. The cryo-flasks were stored in an ethanol-bath at -80°C overnight and then
transferred into liquid nitrogen the next day. The earliest possible passage to obtain
freezes is passage number 3.
C.

MIRNA TRANSFECTION
Once the cell suspension’s concentration was determined, the cells were plated

into separate wells on a 6-well plate at a concentration of 250,000 cells/2mL culture
media and then allowed a 24-hour period to adhere to the plate prior to transfection. At
24 hours, transfection of the following was performed:


miR-99a mimic



miR-99a antagomir
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mimic negative control



antagomir negative control



mimic positive control



antagomir positive control

These were introduced to different individual wells using the Lipofectamine® 3000
Transfection Reagent Protocol. Each cell line was incubated for 72 hours after
transfection prior to cell harvesting.
D.

HARVESTING CELLS (FOR RNA OR PROTEIN)
After isolated cell populations had been transfected or treated with rapamycin,

they were harvested for either total RNA or protein content. The medium was aspirated
carefully and discarded. The cells were rinsed once with ice cold phosphate-buffered
saline (PBS) and cells were then treated with trypsin-ethylenediaminetetraacetic acid
(EDTA). This allows for them to round up in the appropriate media when added to the
plate. The cell suspension was then centrifuged at 125g for 6 minutes at 37°C until a
pellet was formed. The cell pellet was re-suspended with 1mL of 1x PBS and centrifuged
into a pellet. If harvesting for total RNA, the cells were re-suspended using 0.4 mL of ice
cold lysis buffer. If harvesting for protein, the cells were re-suspended using 0.15 mL of
ice-cold radio immune-precipitation assay (RIPA) buffer. The cells and buffer are mixed
thoroughly by pipetting and then stored at -80°C until needed.

E.

POLYMERASE CHAIN REACTION
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Cell samples in lysis buffer were prepared first via reverse transcription for
microRNA quantification using a Step-One™ RT-PCR® System with default long
thermal cycling conditions. Using the TaqMan miRNA reverse transcription kit and
TaqMan microRNA-specific primer pool (5x), targeted RNA was converted into cDNA
in a thermal cycler. TaqMan probes (20x) were used to bind to complementary sequences
on target cDNA during quantitative RT-PCR. The levels of miRNA-99a were normalized
to miRNA RNU6, an endogenous internal reference, in order to calculate ΔCT values.
ΔCT values of samples transfected with miRNA-99a mimic and antagomir were
compared to the ΔCT values of corresponding positive and negative controls.
F.

WESTERN BLOT
For protein quantification, western blots (n=4 for each protein) were performed

for target proteins in the mTOR pathway (Table 16). After the sample was thawed on ice
from its -80°C storage, 0.001 mL of protease inhibitors were added. The cells were then
sonicated to disrupt cellular membranes. The cell debris was centrifuged into a pellet. To
determine the total concentration of protein in the sample, a bicinchoninic acid (BCA)
assay was performed. The supernatant of the sample was then diluted by a factor of 20
with double distilled water in a 96 well plate. For reference, concentration standards from
0 to 1000ng/µL were added to appropriate wells. All wells were then treated with
0.16mLs of BSA assay and allowed to incubate at 37°C for 30 minutes. After incubation,
the plates were then analyzed using Titertek Multiskan MCC/340® microplate reader
which produced protein concentration of the samples in question.
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An appropriate percentage Bolt® Bis-Tris Plus Gel was placed in the Bolt® Mini
Gel Tank which was then filled half-way with running buffer. The wells were then loaded
with molecular marker standards and cell protein samples ranging from 40 to 100
micrograms. Finally the remainder of the tank was filled with running buffer. The gels
were run at 165mV for 35-90 minutes to run the molecular markers off the gel depending
on the size of the protein of interest.
Proteins of interest in the mTOR pathway, their molecular weight (MW), and
predicted band sizes are listed in Table 17.
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Table 17. mTOR pathway proteins of interest with molecular weight and predicted
Western Blot band detection size.

Protein

Observed Molecular Weight

Predicted Band Size (kDa)

(kDa)
mTOR

289

>250

RAPTOR

149

149

RICTOR

192

192

eIF4g1

175

220

S6K1

70

70 and 85123

eIF4EBP1

13

20,22, and 25
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The completed gel with separated proteins is then transferred onto a
Polyvinylidene difluoride (PVDF) membrane using the iBlot® Gel Transfer Device
(protocol reference). The PVDF membrane was then cut to an appropriate size, covered
in 5% milk, and rocked for 1 hour at room temperature in order to block proteins.
Primary antibodies for target proteins were prepared in 5% milk and poured over the
membrane which was then rocked for another 1 hour at room temperature. The
membrane was washed for 10 minutes with Tris-buffered Saline and Tween 20 (TBS-T),
and then covered with the secondary antibody which was also prepared in 5% milk and
rocked for 1 hour at room temperature. The membrane was again washed for 10 minutes
with TBS-T.
1-1.5mL of Enhanced chemiluminescence (ECL) reagents A and B, which react
with the horseradish peroxidase (HRP) enzyme on the secondary antibody to produce
light, was applied to each membrane in order to detect the target protein. The membrane
and ECL substrates were left in the dark room for 2 minutes before the excess ECL was
removed and the membrane was placed in a plastic cassette and left in the dark room.
G.

CELL MIGRATION ASSAY
To determine the migration properties of the cell lines themselves Boyden

chamber assays were utilized. Five assays were performed for each cell line. First
described by Boyden in 1962, these assays allow for the cells chemotactic behavior to be
determined.124 This assay separates two chambers with a microporous membrane (8 μm
pore size). After transfection has occurred the cells under study are then seeded into in
the upper chamber. In this step the cells can be “starved” to a certain degree. In all assays
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used in my studies, the FBS percentage was reduced from 10%, which is the percentage
we use in day to day maintenance, down to 1% in this assay. This helps to promote cells’
movement, once they have been starved for a period of time. They are allowed to settle in
this chamber for 24 h without chemoattractant added to the bottom chamber. 24 hours
after plating the cells into the upper chamber the addition of media with 20% FBS is
added to the bottom chamber. Then the cells are allowed to migrate for 12 h. (Figure 7)
At the 12 h mark the cells are observed under light microscopy and then stained to allow
for quantification in a plate reader. The cells were stained with Blue Cell Stain Solution
(Cell Biolabs, Inc.) and then extracted to read at 560nm in the plate reader.
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Figure 7. Cell migration diagram and experimental steps
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H.

CELL INVASION ASSAY
Similar to the Boyden migration assay, the invasion assay now coats the

microporous membrane (8 μm pore size) with a uniform layer of dried basement
membrane matrix solution. This layer allows for discrimination between invasive and
non-invasive cells. If the cells have invasive properties then they will be able to degrade
this matrix membrane solution and then migrate through the 8 μm pores that are present
in the polycarbonate membrane inserts. (Figure 8) Similar to the migration assay, the
cells are allowed 24 hours to settle after plating into the upper chamber. The upper
chamber cells are once again “starved” with 1% FBS containing media. At the 24 hour
time point, 20% FBS containing media is added to the bottom chamber. At the 12 hour
mark the cells that have migrated are stained and the utilization of the plate reader at
560nm is used to determine the amount of cells that migrated. Five assays were
performed for each cell line.
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Figure 8. Cell invasion diagram and experimental steps
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I.

STATISTICAL ANALYSIS
To analyze statistical significance of the Western blot assays and

migration/invasion studies we utilized the unpaired t-test. All data was analyzed in SPSS,
(SPSS Inc. Released 2007. SPSS for Windows, Version 16.0. Chicago, SPSS Inc.) using
a two tailed analysis. All sample sizes were equal and had a normal distribution.
Statistical significance was defined as a p ˂ 0.05.
For Western Blot samples all data had a sample size equal to four, unless noted.
These were four cell culture samples that were each grown from new freezes, transfected
at the same pass generation and transfected in the same fashion to give a true sample size
of four. The same was done for the migration/invasion assay, except the sample size was
increased to five.
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CHAPTER VI
TRANSFECTION OVERVIEW, PRELIMINARY RESULTS AND DISCUSSION
A.

INTRODUCTION

Transfection is the process of introducing an external nucleic acid into the normal
functioning cell. In our experiments we utilize two types of non-viral transfection. The
use of mimic and antagomirs were used to accomplish our goals. Mimic transfections
occur when the investigator introduces more of what we are trying to upregulate. In our
experiments with miRNA-99a, by introducing miRNA-99a mimics we are increasing the
amount of active miRNA-99a into the cell’s cytoplasm. The opposite occurs when we
introduce an antagomir into the cell’s cytoplasm. miRNA-99a antagomir ultimately
down regulates the available amount of active miRNA in question.
Transfecting antagomirs tend to be more finicky and less successful than mimic
reactions as it is more difficult to completely eliminate a resource from a cells
environment than it is to add to it.
The use of miRNA mimics and antagomirs in transfection experiments allows us
to manipulate cell line behavior and protein expression. Once transfection had occurred
the first step is to verify the success or failure of the transfection.
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B.

DATA AND RESULTS
Real time polymerase chain reaction (qRT-PCR) is used to verify successful or

unsuccessful transfection. Initially HT-29 cell line was investigated. HT-29 was allowed
to grow and when appropriate amounts of cells were available seeded into 6 well culture
plates. After 24h, after proper seeding and settling of transfection with miRNA-99a
mimic, mimic negative control, antagomir and antagomir negative control was
performed. We used Lipofectomine 3000® following manufacture’s protocol. This was
repeated with CCD841 and HCT116 cell lines.
Data regarding transfection of HT-29 is shown in Figure 9. The mi-RNA99a
mimic transfection was associated with a fold change of miRNA 99a expression of 8750
as compared to the antagomir transfection which was associated with a miRNA 99a fold
change of 0.065 (fold regulation of 15.2).
Next HCT-116 cell line was transfected, and verified via qRT-PCR. HCT-116
showed an increase in miRNA-99a expression as compared to the non-transfected
control, however, the antagomir was closer to baseline expression and not down regulated
(Figure 10).
After successful transfection of HT-29 and HCT-116, our attention turned to the
transfection of CCD 841 (normal colon epithelial cells). Once again successful
transfection was verified via qRT-PCR, and is shown in Figure 11. Similar to HCT-116
transfection, CCD 841 cells exhibited a fold change in miRNA 99a expression of 34 with
transfection of miRNA-99a mimic. Transfection with the antagomir was not as
successful. We observed a fold change of 1.4 in miRNA 99a expression, which is
78

opposite of what we would expect, ie. a down regulation with the introduction of an
antagomir. All data was corrected for cell number in the analysis of fold change and fold
regulations.
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Figure 9. HT-29 Fold Change of miRNA-99a Expression after Transfection (n=2)
Error bars = standard error of the mean

80

Figure 10. HCT-116 Fold Change of miRNA-99a Expression after Transfection (n=2)
Error Bars = Standard Error of the Mean
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Figure 11. CCD-841 Fold Change of miRNA-99a Expression after Transfection (n=2)
Error Bars = Standard Error of the Mean
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C.

DISCUSSION
The process of transfection allows the investigator to up- or down-regulate certain

elements of cell lines so we can investigate the effects they have on the cells. In this case,
we wish to investigate how the expression of miRNA-99a affects cell protein expression
and ultimately motility and invasion. Key to this process is verification that successful
transfection has occurred.
These data suggest that in HT-29, transfection of miRNA-99a was successful with
both the mimic and antagomir. The fold change for the mimic was well over 1000. In
addition, the antagomir transfection of miRNA-99a in HT-29 resulted in down regulation
of miRNA 99a expression. This was the only cell line in which the antagomir actually
showed downregulation as compared to the negative control.
Although the fold change observed in HCT-116 was not to the same degree as
with HT-29, it was also upregulated in comparison to the negative control. The antagomir
did not show down-regulation of miRNA 99a expression when compared to the negative
control.
When investigating the CCD 841 (normal epithelial cell line), the transfection
data were not as satisfactory as for HT-29 and HCT-116. While transfection with the
miRNA 99a mimic did result in a mild upregulation in miRNA 99a expression as
compared to the negative control, this was relatively small, only a fold change of 38. This
is the trend that we expected but when compared to the CRC cell lines the transfection
did not demonstrate an impressive fold change.
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However, successful transfection of the mimic occurred in all three cell lines
allowing us to proceed with further analyses. Less promising results occurred with the
antagomir. Although, HT-29 showed a negative fold regulation, CCD-841 and HCT-116
minimally exceeded zero. This is not surprising as it is somewhat difficult to completely
block the activity of naturally occurring miRNAs in the cell. One possible solution to this
is, in future studies, not covered in this thesis, would be to utilize miRNA knock out
experiments.
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CHAPTER VII
WESTERN BLOT STUDIES
In order to study the effect of miRNA 99a upon the mTOR pathway it is
necessary to study proteins that mTOR has an effect on. We chose to do this utilizing
western blot analysis. The mTOR pathway has several proteins of interest that can be
investigated, mTOR itself along with RAPTOR, RICTOR, S6K1, ieF4EG-1 and
eiF4EBP-1 to name a few. The complexity of the mTOR pathway can be seen in Figure
12, which only shows the input of AKT into mTORC1. As stated in the introduction,
mTOR has many pathways that converge on mTORC1 and which ultimately influence
several vital processes in protein production and cell motility.
Part of the difficulty, when investigating the mTOR pathway, is dealing with the
active forms of the protein. In some cases, the phosphorylation will activate the protein
whereas in other cases, phosphorylation will inactivate the protein. This is demonstrated
with the phosphorylation of 4EBP1. When 4EBP1 is phosphorylated directly via
mTORC1, it inactivates 4EBP1. The same occurs when 4EBP1 is phosphorylated directly
by MSK1. This becomes confusing as 4EBP1 can also be inactivated by PP2A catalytic,
as shown in Figure 13.
PP2A catalytic is somewhat of a regulator between 4EBP1 and p70 S6 Kinase 1
(S6K1). mTORC1 phosphorylates both proteins, but in each case acts differently. 4EBP1
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when phosphorylated is inactivated, but when TORC1 phosphorylates S6K1 it is
activated. Then PP2A catalytic comes into play. It dephosphorylates both S6K1 and
4EBP1, but when it does this it activates 4EBP1 and inactivates S6K1. This is seen in
Figure 13, where the red +P indicates that phosphorylation inactivates the protein and the
green -P indicates that dephosphorylation activates the protein. In addition the red - P
indicates that dephosphorylation inactivates the S6K1.
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Figure 12. Mechanistic Target of Rapamycin Pathway focusing on AKT input into
mTORC1

*Modified from https://portal.genego.com/cgi/imagemap.cgi?id=496
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Figure 13. mTOR pathway focusing on mTORC1 output on S6K1 and 4EBP1 (enlarged
central portion of Figure 11)

*Modified from https://portal.genego.com/cgi/imagemap.cgi?id=496
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RAPAMYCIN STUDIES
Prior to investigating the effects that miRNA-99a had on the mTOR pathway
itself, we wanted to witness what the cells response to direct rapamycin dosing would do.
To initially do this we wanted to establish a dosing curve to recognize the optimum dose
of rapamycin that would kill 50% of the cells alive in culture.
We utilized MTT assay to establish this curve and the results are shown in Figure
14. After multiple attempts with different concentrations of rapamycin to decrease the
cell culture growth, we found that rapamycin directly did not reliably decrease the
cellular concentration and this finding had been reported previously but in a different
cancer cell line.125
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Figure 14. MTT assay dosing curve of increasing Rapamycin dosing concentrations in
HT-29, HCT-116 and CCD-841. Two different concentrations of plated cell
density denoted in the key.
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CHAPTER VIII
SPECIFIC AIM 1: TO DETERMINE THE EFFECT OF MIRNA-99A’S ON MTOR
PROTEIN PHOSPHORYLATION
A.

INTRODUCTION

Initially we intended to investigate mTOR, RICTOR and RAPTOR proteins and
determine if transfection with miRNA-99a would change their expression. However as
the RICTOR and RAPTOR proteins are part of the mTOR complex, we chose instead to
focus our investigations on the levels of mTOR itself and not the individual proteins of
these complexes. It has not, to our knowledge, been shown whether the phosphorylation
or dephosphorylation of RICTOR or RAPTOR changes the activity of mTORC1 or
mTORC2. It has however been shown that miRNA-99a directly binds to and inhibits
mTOR protein itself.126
The decision was made to investigate direct levels of mTOR protein and several
of the downstream proteins that the mTOR pathway has been shown to influence. These
proteins include S6K1, 4EBP1 and eIF4G1. These proteins were investigated in HT-29,
HCT-116 and CCD-841 cell lines. We chose to limit our study to cell lines derived from
cancers with regional and distant metastasis as this would allow us to study changes in
protein expression that may correlate with significant survival differences seen in these
cancer stages clinically and therefore be possible targets for therapeutic intervention.
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B.

DATA AND RESULTS

To answer specific aim 1, we needed to determine the effect of miRNA-99a upon
mTOR protein itself. To do this we utilized Western blot assay after transfection of the 3
cells lines with miRNA-99a mimic.
Initially CCD-841 (normal epithelial CRC cells) underwent Western Blot
analysis. Both antibodies for total mTOR and phosphorylated only had a similar trend
showing downregulation after transfection compared to the negative control.
When the Western Blots were analyzed for mTOR total after transfection with
miRNA99a, the CCD-841 showed a relative density of 0.022 ± 0.013 (Figure 15). When
compared to the negative control which resulted in a relative density of 0.081 ± 0.051.
This was not statistically significant with p = 0.14.
Similarly, CCD-841 relative density from Western Blot analysis of
phosphorylated mTOR after miRNA-99a mimic was transfected resulted in a value of
0.04 ± 0.01(Figure 16). This is compared to the negative control after transfection which
resulted in a value of 0.06 ± 0.01. This was not statistically significant with a p value
equal to 0.19. Although not statistically significant, with n=4 all Western Blots studied
had the same trend. When investigation the normalized percentage of total antibody and
phosphorylated compared to the negative control, this resulted in 27% and 73%
respectively.
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Figure 15. Western blot and bar graph of total mTOR protein expression when miRNA99a mimic is transfected in normal epithelial colon cell line CCD-841. Bar
chart is expressed in relative density units.
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Figure 16. Western blot and bar graph of phosphorylated mTOR protein expression when
miRNA-99a mimic is transfected in normal epithelial colon cell line CCD841. Bar chart is expressed in relative density units.
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HT-29 was then investigated. We probed the transfected cells for both
phosphorylated and total mTOR protein expression. We observed a relative density
expression of 0.06 ± 0.02 relative density units for phosphorylated mTOR when
compared to beta actin following transfection with miRNA-99a. This was not statistically
significant (p = 0.07) when compared to the negative control (0.15 ± 0.05), yet with an n
= 4 the trend of downregulation was consistent. These results are shown graphically in
Figure 17. Probing for total expression of mTOR in HT-29 cell line was unsuccessful
despite using 16 different mTOR antibodies; this could be due to non-specific binding of
antibodies to other proteins. When investigation the normalized percentage of total
antibody and phosphorylated compared to the negative control, this resulted in 42% and
186% respectively.
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Figure 17. Western blot and bar graph of phosphorylated mTOR protein expression when
miRNA-99a mimic is transfected in HT-29 CRC cell line. Bar chart is
expressed in relative density units.
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Finally we investigated phosphorylated and total mTOR expression after miRNA99a transfection in the HCT-116 cell line. Although not significant, probing for mTOR
total had the same trend as when we probed for the phosphorylated only mTOR(Figure
18). Similarly to HT-29, transfected cells with miRNA99a were downregulated compared
to the negative control. This downregulation was statistically significant when probing
for phosphorylated mTOR but not total mTOR (Figure 18-19). When investigation the
normalized percentage of total antibody and phosphorylated compared to the negative
control, this resulted in 51% and 640% respectively.
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Figure 18. Western blot and bar graph of total mTOR protein expression when miRNA99a mimic is transfected in HCT-116 CRC cell line. Bar chart is expressed in
relative density units.

99M
99A
MACON+

mIR 99a Mimic transfected
mIR 99a Antagomir transfected
mIR 99a negative mimic transfected (Mimic Sham)
mIR 99a negative antagomir transfected (Antagomir Sham)
Purchased positive control cell lysate

98

Figure 19. Western blot and bar graph of phosphorylated mTOR protein expression when
miRNA-99a mimic is transfected in HCT-116 CRC cell line. Bar chart is
expressed in relative density units.

99M
99A
MACON+

mIR 99a Mimic transfected
mIR 99a Antagomir transfected
mIR 99a negative mimic transfected (Mimic Sham)
mIR 99a negative antagomir transfected (Antagomir Sham)
Purchased positive control cell lysate

99

C.

DISCUSSION

In order to answer specific aim 1, we needed to limit our focus to miRNA-99a’s
effect on the total and phosphorylated mTOR protein levels after transfection. We
expected, with the introduction of miRNA-99a mimic, the expression of phosphorylated
mTOR protein would decrease in comparison to the mimic negative control. This trend
was observed in all three cell lines under study.
HCT-116 when probing for phosphorylated only mTOR was the only cell line
statistically significant. Although this may be the case, all of the above studies had a
similar trend which was promising for future experiments.
We then investigated total mTOR protein expression after transfection of miRNA99a mimic. This was successful in HCT-116 and normal epithelial cell line CCD-841, but
we were unable to optimize an antibody for Western Blot detection with the HT-29 cell
line. This could be due to lack of interaction with that particular primary antibody or
mTOR not being expressed readily in that particular cell line. The latter is unlikely as
phosphorylated mTOR was detected in this same cell line. The data for HCT-116 and
CCD-841 reaffirmed our results from the phosphorylated-mTOR data and suggest that
when miRNA-99a is introduced into the cell culture environment, there is a resulting
down-regulation of both phosphorylated and total mTOR protein expression.
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CHAPTER IX
SPECIFIC AIM 2: THE EFFECT OF MIRNA-99A’S EFFECT ON S6K1 AND 4EBP1
A. INTRODUCTION
Our attention now focused on downstream proteins of the mTORC1 complex. The
ultimate goal being to answer specific aim two, which was to determine the effect of
miRNA-99a on the phosphorylation of mTOR pathway’s downstream proteins. Initially,
we performed Western blot analysis of phosphorylated S6K1 and total S6K1 expression
in HT-29 cell line, followed by evaluation of cell lines HCT-116 and CCD-841. The
same was then performed for 4EBP1.
B. DATA AND RESULTS
1. S6K1
Initially CCD-841, normal epithelial cell line, showed the expected result of
downregulation after transfection with miRNA-99a. After transfection, S6K1 relative
density expression was 0.018 ± 0.007 compared to the negative control 0.026 ± 0.008
(Figure 20). This comparison was statistically significant with a p value equal to 0.008.
When investigation the normalized percentage of total antibody and phosphorylated
compared to the negative control, this resulted in 70% and 75% respectively.
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Figure 20. Western blot and bar graph of phosphorylated S6K1 (75 KDa) protein
expression when miRNA-99a mimic is transfected in normal colon epithelial
cell line CCD-841. Bar chart is expressed in relative density units.

99M
99A
MACON+

mIR 99a Mimic transfected
mIR 99a Antagomir transfected
mIR 99a negative mimic transfected (Mimic Sham)
mIR 99a negative antagomir transfected (Antagomir Sham)
Purchased positive control cell lysate

102

HT-29 cell line was then transfected with miRNA-99a, and then mTOR total was
probed for in the Western Blot studies. This resulted in a significant difference (p = 0.02)
between miRNA-99a mimic and its transfected negative control (Figure 21). Once again
the same pattern was observed after transfection, a downregulation of S6K1 compared to
negative control.
Finally, HT-29 cell line was transfected with miRNA-99a and probed for
phosphorylated only S6K1. This resulted in Western Blot analysis that showed a relative
density measurement of 0.19 ± 0.04. This was compared to the transfected negative
control which resulted in a relative density of 0.22 ± 0.07 (Figure 22). This was not
statistically significant (p = 0.15) but all samples had the expected downregulation of
S6K1 after transfection when compared to the negative control. When investigation the
normalized percentage of total antibody and phosphorylated compared to the negative
control, this resulted in 90% and 86% respectively.
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Figure 21. Western blot and bar graph of total S6K1 (70 KDa) protein expression when
miRNA-99a mimic is transfected in HT-29 CRC cell line. Bar chart is
expressed in relative density units.
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Figure 22. Western blot and bar graph of phosphorylated S6K1 (70 KDa) protein
expression when miRNA-99a mimic is transfected in HT-29 CRC cell line.
Bar chart is expressed in relative density units.
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Once again we investigated both HCT-116 and CCD-841 for S6K1. The antibody
probes were successful only when probing for phosphorylated antibodies and were not
successful for total expression. HCT-116 phosphorylated resulted in a different pattern
than expected. When transfected with miRNA-99a mimic it was upregulated (0.09 ±
0.02) compared to the negative control (0.06 ± 0.02, Figure 23). Although not statistically
significant (p = 0.11) this was an interesting result as it happened in all 4 samples and
was the first experiment that showed this type of pattern after transfection. When
investigation the normalized percentage of total antibody compared to the negative
control, this resulted in 164% change.
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Figure 23. Western blot and bar graph of phosphorylated S6K1 (70 KDa) protein
expression when miRNA-99a mimic is transfected in HCT-116 CRC cell line.
Bar chart is expressed in relative density units.
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2. 4EBP1
Figure 12 shows the mTORs pathway direct interaction with 4EBP1. When
mTOR is active and phosphorylates 4EBP1 it turns 4EBP1 off, this is the opposite of
what mTOR does to the protein S6K1. Now that S6K1 was elucidated in the cell lines
under study, we next wanted to see how miRNA-99a would influence the
phosphorylation of 4EBP1.
First CCD-841 underwent Western blot analysis for 4EBP1 after transfection with
miRNA-99a. The phosphorylated only Western Blots resulted with the same average
across 4 samples (Figure 24). Both the negative control (0.16 ± 0.09) and transfected cell
lines (0.16 ± 0.11) basically showed no difference.
Investigating total expression we saw upregulation of 4EBP1 after transfection
with miRNA-99a compared to negative control (Figure 25). After transfection with
miRNA-99a, a relative density of 0.14 ± 0.12 resulted compared to the negative control
equal to 0.18 ± 0.14. Once again the p value was not statistically significant but it was
approaching significance (p = 0.06). When investigating the normalized percentage of
total antibody and phosphorylated compared to the negative control, this resulted in 78%
and 98% respectively.
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Figure 24. Western blot and bar graph of phosphorylated 4EBP1 (15-20 KDa) protein
expression when miRNA-99a mimic is transfected in normal colon epithelial
control cell line CCD 841. Bar chart is expressed in relative density units.
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Figure 25. Western blot and bar graph of total 4EBP1 (15-20 KDa) protein expression
when miRNA-99a mimic is transfected in normal colon epithelial control cell
line CCD 841. Bar chart is expressed in relative density units.
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After this, HT-29 was transfected with miRNA-99a and then underwent Western
Blot analysis for total and phosphorylated only relative density measurements of 4EBP1.
Figure 26 shows the results of phosphorylated only 4EBP1, which is 0.46 ± 0.11 for
miRNA-99a mimic compared to the negative control, 0.42 ± 0.09. This was not a
statistically significant comparison with p = 0.28 for our 4 samples but once again all had
a similar trend.
Next, probing for total expression of 4EBP1 shows a similar upregulation
compared to negative control trend, although it is still not statistically significant (p =
0.28). After miRNA-99a transfection the relative density average was 1.17 ± 0.87
compared to the negative control average of 0.87 ± 0.60 (Figure 27). When investigation
the normalized percentage of total antibody and phosphorylated compared to the negative
control, this resulted in 135% and 108% respectively.
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Figure 26. Western blot and bar graph of phosphorylated 4EBP1 (15-20 KDa) protein
expression when miRNA-99a mimic is transfected in HT-29 cell line. Bar
chart is expressed in relative density units.
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Figure 27. Western blot and bar graph of total 4EBP1 (15-20 KDa) protein expression
when miRNA-99a is transfected in HT-29 cell line. Bar chart is expressed in
relative density units.
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Once again after elucidating the trend in Dukes C CRC cell line, our attention
next focused on HCT-116, Dukes’ D cell line. After transfection, Western Blot analysis
showed a relative density of 0.21 ± 0.11 compared to the negative control 0.24 ± 0.04
(Figure 28). Similarly the antibodies that detected total protein expression and not just
phosphorylated had a similar trend with the mimic being downregulated (1.61 ± 0.27)
compared to the negative control (1.78 ± 0.36, Figure 29). Both of these sets of Western
Blots were not statistically significant with p values of 0.31, 0.25 respectively but all had
a similar trend. This is interesting because this trend is the exact opposite of the Dukes’ C
and normal epithelial cell lines when probing for not only 4EBP1 but also S6K1. Finally,
when investigating the normalized percentage of total antibody and phosphorylated
compared to the negative control, this resulted in 91% and 85% respectively.
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Figure 28. Western blot and bar graph of phosphorylated 4EBP1 (15-20 KDa) protein
expression when miRNA-99a mimic is transfected in HCT-116 cell line. Bar
chart is expressed in relative density units.
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Figure 29. Western blot and bar graph of total 4EBP1 (15-20 KDa) protein expression
when miRNA-99a mimic is transfected in HCT-116 cell line. Bar chart is
expressed in relative density units.
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C. DISCUSSION
In our study, we focused only on HT-29 and HCT-116 cell lines as well as one
normal colon epithelial cell line. This decision to limit our study to these two cell lines
can be justified as our ultimate goal is to uncover the mTOR pathways’ influence on
CRC metastatic potential. By focusing on these two cell lines, it allows us to limit our
study to cell lines that are defined by their metastatic properties, HT-29 being derived
from a cancer characterized by regional metastasis and HCT-116 derived from a cancer
characterized by distant metastasis.
Our first step when investigating the mTOR pathway is to initially see if mTOR
protein itself is affected when miRNA-99a is transfected into the cell line. It has been
shown that miRNA-99a directly interacts with mTORC2 complex.126 miRNA-99a has
been shown to directly bind to this complex and repress its expression. We showed
through Western blot analysis that transfection of miRNA-99a does indeed reduce the
amount of both total and phosphorylated mTOR protein in all studied cell lines. Once this
was established our focus turned to addressing specific aim two.
In order to answer specific aim two, we queried downstream effectors of
mTORC2. Once we established that miRNA-99a had an effect on the overall expression
of the active or phosphorylated form of mTORC1 and mTORC2 we wished to see what
effect this down-regulation had on the proteins that mTORC1 directly targets. Initially we
investigated the effect of miRNA-99a on S6K1.
One of the key roles of mTORC1 and its interaction with S6K1 is the regulation
of cell growth and metabolism leading to its predictable role in aberrant cellular growth,
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i.e. in cancer.127 After we noted the effects that miRNA-99a had on the mTOR protein
itself, it was key to study the phosphorylation or de-phosphorylation of S6K1. It has been
shown in other cancers and disease states that when mTORC1 is active, it phosphorylates
S6K1, which is thereby activated.
In our experiments, we would predict that if mTOR phosphorylation would be
down-regulated as compared to the negative control, we would expect S6K1 to also to be
down-regulated. This is what occurred in the HT-29 cell line as well as in CCD-841. In
addition, in the HT-29 cell line total S6K1 was down-regulated as compared to the
negative control. In our data, miRNA-99a down-regulates the active form of mTORC1
and this down-regulation directly affects the phosphorylation of S6K1. Thus by
decreasing the amount of active mTORC1, the phosphorylation and thus the active form
of S6K1 is reduced.
The behavior of the HCT-116 line is opposite that of the HT-29 and CCD 841 cell
lines. Thus, when miRNA-99a mimic is introduced into the cells, we observed an upregulation of the phosphorylation of S6K1as compared to the negative controls. There are
at least two possible explanations for this: there are multiple pathways that ultimately
converge on mTORC1, thus in this particular cell line, another pathway could be the
predominate regulator of mTOR and override the effects of miRNA-99a on S6K1
phosphorylation. In addition as seen in Figure 2, mTORC1 can directly phosphorylate
S6K1, SGBP1 or 4EBP1. If mTOR predominantly phosphorylates IGBP1, this will then
go on to dephosphorylate S6K1 via the PP2A catalytic pathway. One more possibility
that could explain HCT-116’s different behavior, in comparison to the other two cell
lines, is that HCT-116 is a mismatch repair deficient (Hereditary Non-polyposis
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Colorectal Cancer [HNPCC]) cell line. This means that the mutation that leads to CRC in
this cell line is different from that seen in sporadic CRC and normal tissue (our HT-29
and CCD-841 cell lines). HNPCC is defective in DNA mismatch repair genes MSH2,
MLH1, MSH6, PMS2, PMS1, TGFBR2 or MLH3, ultimately leading to microsatellite
instability.117-120, 122 The fact that the pathology of this disease state is altered in
comparison to sporadic CRC, could possibly lead to some of the different results
observed with the HCT-116 cell line. The HCT-116 is a commonly utilized CRC cellline, and the fact that it is mismatch repair deficient is not widely appreciated. This is has
great impact on much published literature.
We also wished to further investigate one other downstream protein of the mTOR
pathway (4EBP1). We chose this protein since mTOR phosphorylation has the opposite
effect on its function as compared to S6K1. The phosphorylation of 4EBP1 results in its
deactivation. We would expect a similar phosphorylation trend to that seen with S6K1.
This was, however, was not the case with all of the cell lines. With HT-29 and CCD-841
cell lines we saw the opposite outcome of what we would have predicted. In the HCT116 cell line we observed what we would expect, i.e. when miRNA-99a mimic is
introduced, phosphorylation of 4EBP1 is downregulated.
In conclusion, it is interesting that the HT-29 and normal epithelial cell line CCD841 behave opposite of the HCT-116 cell line. Thus when miRNA-99a is introduced, in
HT-29 and CCD-841 we observe downregulation of the S6K1 phosphorylation and
upregulation of 4EBP1 phosphorylation. With HCT-116, the exact opposite is observed
with both proteins. A possible explanation for this could be the fact that HCT-116 is a
mismatch repair deficient cancer in contrast to HT-29 and CCD-841 which are both
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mismatch repair proficient. To test this, further work is being done, which is not covered
in this thesis, which will investigate a Dukes D CRC cell line that is mismatch repair
proficient with a Dukes C CRC cell line that is mismatch repair deficient.
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CHAPTER X
SPECIFIC AIM 3: TO DETERMINE IF TRANSFECTION OF HT-29, HCT-116 AND
CCD841 CELL LINES WITH MIRNA-99A WILL INHIBIT CELL MIGRATION AND
INVASION

A. INTRODUCTION
The motility of the cells lines was assessed to answer specific aim three. Since
these cancer cell lines are classified by their metastatic potential, it is necessary to test the
motility and invasion properties of each cell line. First, we needed to study the migration
properties and once that was complete, we investigated the invasive nature of HT-29 and
HCT-116.
Migration was tested first in HT-29 and HCT-116 utilizing the Boyden chamber
method. The Boyden chamber assay allows us to compare migration between transfected
cell lines and negative controls.124 Once the transfection occurs, the transfected cell lines
are then placed into the assay chambers and allowed to migrate into the bottom chamber.
The technical specifications of these methods have been described previously in the
Materials and Methods section (p. 70-72).
Transmigration assays allow us to observe the migration properties of specific
cells in response to different chemoattractants.124 In our case, it allows us to investigate
the migration properties of cells that have undergone transfection. One possible

121

disadvantage of using this type of assay is that cells under study will only migrate if
motivated. In our study we chose to use the cells’ “food” FBS as a chemoattractant. By
seeding the cells in an environment that is “starved,” in theory we give the cells an
incentive to migrate to a place where nourishment is available. To encourage this
movement, our cell lines are originally seeded in a 1% FBS solution while the chamber
that the cells would migrate to had a FBS solution of 20%. Disadvantages of the
procedure are that it is technically challenging, and there is limited cell visualization
while the assay is being performed.
1.

MIGRATION DATA AND RESULTS

Initially we studied HT-29 to observe if transfection with miRNA-99a mimic
would affect cell migration. Our sample size of five resulted in a reduced migration after
miRNA-99a transfection equal to -0.045 ± 0.005, yet this was not statistically significant
(p = 0.31) compared to the negative control (Figure 30). Once again the 5 samples had a
similar trend but was not statistically significant. Turning our attention to the cell lines
transfected with miRNA-99a antagomir, the migration assay was essentially the same as
the transfected negative control (Figure 30).
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Figure 30. HT-29 Migration Assay after transfection with miRNA-99a Mimic (Blue) and
Antagomir (Red). All data is normalized to the negative control.

Figure 30b. Numerical Density Values for HT-29 migration assay

Normalized Migration (n=5)
99M

99A

Average

-0.045

-0.001

Standard Deviation

0.005

0.014

p-value (t-test)

0.312

0.496
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We observed a similar pattern in HCT-116, yet the observed relative density
values were larger in magnitude. After transfection with miRNA-99a mimic a relative
density value after cell migration was equal to an average of -0.325 ± 0.379 which did
approach statistical significance, p = 0.064 (Figure 31).
Similarly as with the HT29 (Dukes C cell line), HCT-116 antagomir assay studies
were basically unchanged from their transfected negative control (Figure 31). This is not
surprising as we did not have great success with the antagomir transfection being
downregulated. Since the transfection was likely unsuccessful we did not expect there to
be a significant influence on the pathway.
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Figure 31. HCT-116 Migration Assay after transfection with miRNA-99a Mimic (Blue)
and Antagomir (Red). All data is normalized to the negative control.

Figure 31b. Numerical Density Values for HCT-116 migration assay

Normalized Migration (n=5)
99M

99A

Average

-0.325

-0.029

Standard Deviation

0.379

0.613

p-value (t-test)

0.064

0.460
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B. MIGRATION ASSAY DISCUSSION
Although the migration assays did not yield statistical significant in any of the
studies, they did show promising results for further inquiry. After transfection in both cell
lines we would predict that a decreased migration would occur when compared to the
negative control. This was observed in all samples but not statistically significant. HCT116 did approach statistical significance, which was promising for future studies.
The most likely reason we observed more migration in the Dukes D cell line
compared to the Dukes C cell line is due to the fact that by definition the Dukes D cell
line is a more aggressive cancer line. Another theory is that due to the fact that HCT-116
is able to replenish the cells that are lost after transfection occurs because of its
aggressive nature, as it has been shown that transfection itself can have a cytotoxic effect
on the cells themselves. 128
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C. INVASION DATA AND RESULTS
The invasion assays once again utilize the Boyden chamber method and the
specific details of experimental materials and method have been discussed previously.124
The difference between the migration and the invasion assays is the membrane coating
that is applied to the Boyden chambers. The migration assay has a non-coated
polycarbonate membrane inserts with 8 μm pores. The invasion assay uses these same
polycarbonate membranes with the same pore size yet it is coated with a dried basement
membrane matrix solution to recreate a functional basement membrane. This is
important because the ability of cells to invade through the basement membrane is
essential to their metastatic potential.
Initially we evaluated the HT-29 cell line. We transfected HT-29 cells with
miRNA-99a mimic and antagomir and then observed the amount of invasion at 48 hours.
Cells transfected with miRNA-99a mimic exhibited minimal invasion. Our sample size of
6 resulted in an average relative density equal to -0.034 ± 0.030, which was not
significant as p = 0.36 (Figure 32). As expected from the migration studies, the
transfected cells with miRNA-99a antagomir did not invade much and had an extremely
wide standard deviation (Figure 32).
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Figure 32. HT-29 Invasion Assay after transfection with miRNA-99a Mimic (Blue) and
Antagomir (Red). All data is normalized to the negative control.

Figure 32b. Numerical Density Values for HCT-116 invasion assay

Normalized Invasion (n=5)
99M

99A

Average

-0.034

-0.023

Standard Deviation

0.030

0.112

p-value (t-test)

0.359

0.349
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Next, we evaluated the invasive properties of HCT-116. The transfection of
miRNA-99a mimic resulted in a relative density measurement of -0.041 ± 0.096(p = 0.20,
Figure 33). The transfection of the antagomir had a density measurement of -0.005 ±
0.111 (p = 0.46, Figure 33), as compared to the negative controls, i.e. there was basically
no invasion with antagomir transfected cell lines as compared to the transfected negative
control.
Overall data from the invasion assays were not as clear cut as those from the
migration assays. Some possible explanations for this:


Prior studies of the HT-29 cell line showed that it had minimal migration and
invasive properties, which could account for the data we observed with this cell
line.129



The motility of the antagomir transfected cell lines could be due to the lack of
successful antagomir transfection.



The effects of transfection itself can be cytotoxic after certain time periods.128
Although Lipofectamine 3000® has not been tested for this to our knowledge, its
predecessor Lipofectamine 2000® was thus tested and found to be cytotoxic.
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Figure 33. HCT-116 Invasion Assay after transfection with miRNA-99a Mimic (Blue)
and Antagomir (Red). All data is normalized to the negative control.

Figure 33b. Numerical values for HCT-116 Invasion Assay

Normalized Invasion (n=5)
99M

99A

Average

-0.041

-0.005

Standard Deviation

0.096

0.111

p-value (t-test)

0.195

0.459
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D. DISCUSSION
The migration data are interesting in that HT-29 and HCT-116 had similar
patterns of migration and invasion after transfection with miRNA-99a mimic. The more
promising data with HCT-116 are not surprising as it has been previously reported that
HT-29 cell lines have limited motility in migration assays.129
The invasion data showed a similar trend as the migration data. Both cell lines
exhibited reduced invasion after miRNA-99a transfection although this was not
statistically significant. Invasion was not observed with either CRC cell line following
antagomirs transfection. This could be due to the difficulty in antagomir transfection that
was previously discussed.
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CHAPTER XI
FINAL DISCUSSION AND OVERVIEW
Colorectal Cancer (CRC) is the third most common cancer in men and women in
the United States.1 According to the Centers for Disease Control and Prevention’s most
recent statistics in 2011 approximately 135,260 people were diagnosed with CRC in that
year alone.1 51,783 reported deaths were credited to CRC, including 26,804 men and
24,979 women.1 Out of all states, Kentucky ranked number one in incidence for male
cases of CRC with 58.8 per 100,000 individuals. Females in the state of Kentucky ranked
#3 out of all states with a rate of 40.6 per 100,000 individuals and combined Kentucky
ranked #1 out of all states at a rate of 48.9 per 100,000 individuals.1 All of these being
well above the national average for new cases of CRC in individual states.
Although these might be daunting statistics, this poses a challenge from the
researchers stand point, as it opens up an opportunity to focus on an area that potentially
could change thousands of lives. CRC if caught early is potentially curable.
One pathway that has currently gained a large amount of attention because of its
implication in cancer metastasis is the mechanistic target of rapamycin the mTOR
pathway. The mTOR pathway is an extensive and complex pathway that has a great deal
of control over the translation of many eukaryotic proteins.
Prior work shows that multiple upstream regulators control mTORC1, these are
not limited to but include PI3K/Akt route to mTORC1.130 It has been shown that the
miRNA family of 99 and 100, which includes miRNA-99a, directly binds to mTORC2.126
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mTORC2 directly interacts with the AKT pathway which is one of the many upstream
regulators of mTORC1.
Our work investigated the mTOR pathway and miRNA-99a’s influence on CRC
cell lines within this pathway. With better understanding of this pathway and the
influence miRNA-99a on this pathway, many avenues of study for potential therapeutic
intervention for metastatic CRC may become available.
A. SUMMARY OF FINDINGS
We initially needed to confirm successful cell line transfection of CCD-841
(normal colon epithelial cell line), HT-29 (Dukes C) and HCT-116 (Dukes D) cell lines.
miRNA-99a mimic was successfully transfected in all three cell lines. This was shown
with representative qRT-PCR transfection results of miRNA -99a indicating upregulation
of expressed miRNA-99a after transfection with miRNA-99a mimic (Figure 9-11).
miRNA 99a antagomir transfection was not as successful (Figure 9-11). Three
cell lines did show a miRNA-99a level close to baseline, however, not all cell lines were
downregulated. Moving forward, we therefore focused our efforts on mimic transfection,
especially when investigating the proteins in the mTOR pathway. We did pursue motility
assays using both mimics and the antagomirs, although we did not expect much success
for the antagomir motility studies due to our limited results with antagomir transfection.
To answer Specific Aim 2, we utilized Western blot analysis of mTOR protein,
S6K1 and 4EBP1. Most data was in agreement to what one would predict after
transfection with a miRNA-99a mimic. Our data showed HT-29 phosphorylated average
relative density of 0.06 ± 0.02 compared to the negative control 0.15 ± 0.05, although not
133

statistically significant (p = 0.07) it did have the same trend in all samples. This is what
we would predict as miRNA-99a has been shown to directly bind to mTORC2 and to
down-regulate this protein.126
A similar pattern of mTOR was seen after transfection in HCT-116 and CCD-841.
In HCT-116 an average relative density of phosphorylated antibodies was 0.03 ± 0.00.
This was compared to the negative controls average of 0.05 ± 0.04. Which was a
statistically significant difference (p = 0.04). The total antibody resulted an average
density of 0.13 ± 0.13 compared to the negative control of 0.25 ± 0.23, which was not a
significant difference (p = 0.23). Finally, the CCD-841 cell lines, resulted in
phosphorylated density average of 0.04 ± 0.01 compared to the negative control which
was equal to 0.06 ± 0.01. This was not statistically significant, p = 0.19. Probing for the
total antibody resulted in an average of 0.02 ± 0.01 compared to the negative control
which was equal to 0.08 ± 0.05 (p = 0.14).
S6K1 phosphorylated only Western blot analysis resulted in a relative density
measurement of 0.19 ± 0.04. This was compared to the transfected negative control
which resulted in a relative density of 0.22 ± 0.07, which was not statistically significant
(p = 0.15) but all samples had the same trend. mTOR total probe resulted in a significant
difference (p = 0.02) between miRNA-99a mimic and its transfected negative control.
The average density after transfection was 0.09 ± 0.07 compared to the negative control,
0.10 ± 0.07.
Then 4EBP1 was elucidated under Western blot analysis. HT-29 cell line shows
the results of phosphorylated only 4EBP1, which is 0.46 ± 0.11 for miRNA-99a mimic
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compared to the negative control, 0.42 ± 0.09. This difference was not statistically
significant with p = 0.28. Next, total expression of 4EBP1 shows a similar upregulation
compared to negative control trend, with the relative density average being 1.17 ± 0.87
compared to the negative control average of 0.87 ± 0.60, which was not significantly
different.
Our attention next shifted to HCT-116, the Dukes’ D cell line. Western blot
analysis showed a relative density of 0.21 ± 0.11 compared to the negative control 0.24 ±
0.04. Similarly, the total protein was downregulated (1.61 ± 0.27) compared to the
negative control (1.78 ± 0.36). Neither were statistically significant with p values equal to
0.31, 0.25 respectively.
Finally CCD-841 phosphorylated only versus negative control Western blots
basically showed no difference, 0.16 ± 0.09 compared to 0.16 ± 0.11 respectively. 4EBP1
total expression showed upregulation after transfection with miRNA-99a compared to
negative control. A relative density of 0.14 ± 0.12 was compared to the negative control
equal to 0.18 ± 0.14. Once again the p value was not statistically significant but it was
approaching significance (p = 0.06)
Out of all the Western Blots only three showed statistical significance compared
to the negative control. When HCT-116 was evaluated for phosphorylated only mTOR.
Next when HT-29 was evaluated for total S6K1. Finally, when CCD841 was evaluated
for phosphorylated only S6K1.
The migration data for HT-29 and HCT-116 were similar to what was predicted.
With the introduction of miRNA-99a mimic a decrease in motility was observed in both
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cell lines. Although this was the appropriate trend, neither of these data sets was
statistically significant. The antagomir transfection assays did not show much difference
compared to the non-transfected cells.
The invasion data showed a similar trend after miRNA-99a mimic transfection.
HT-29 and HCT-116 both exhibit decreased invasion following miRNA-99a transfection,
but once again neither were statistically significant compared to negative control but all
samples had a similar trend. Similar to the migration data the antagomir studies showed
no difference. This was predicted due to the unsuccessful transfection of the antagomirs
that was observed.
Overall, our data are promising for future studies. They highlight the role of
miRNA-99a and its effect in the up and down-regulation of colorectal cancer cell lines.
This is promising as it could open up avenues of possible therapeutic intervention. This
thesis was limited only to cell lines of have a high degree of metastatic potential. Future
studies would need to be done to delineate the impact of miRNA-99a on cancer cell lines
of lesser metastatic potential. In addition future studies need to be undertaken to examine
the difference between mismatch repair proficient and deficient CRC.
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APPENDIX:
ABBREVIATIONS
99M

miRNA-99a mimic

99A

miRNA-99a antagomir

M-

miRNA-99a mimic negative control

A-

miRNA-99a antagomir negative control

AUC

Area Under the Curve

BC

Breast Cancer

BCA

Bicinchoninic acid

CA 19-9

Carbohydrate antigen 19-9

CAA

Colorectal Advanced Adenomas

CCSP

Colon-cancer-secreted-protein

CEA

Carcinoembryonic antigen

CRC

Colorectal Cancer

CSA

Colon cancer specific antigen

CT

Cycle threshold

DMSO

Dimethyl sulfoxide

eIF4EBP1

Eukaryotic translation initiation factor 4E-binding protein 1

EtOH

Ethanol

FBS

Fetal bovine serum

HKG

Housekeeping gene

LC

Lung Cancer

miRNA

micro-Ribonucleic acid

mTOR

Mechanistic target of rapamycin

mTORC1

mTOR Complex 1
145

mTORC2

mTOR Complex 2

PBS

Phosphate buffered saline

PC

Pancreatic Cancer

PVDF

Polyvinylidene difluoride

qRT-PCR

Real time polymerase chain reaction

RCF

Relative centrifugal force

RISC

RNA-induced silencing complex

ROC

Receiver operating characteristic

S6K1

Ribosomal protein S6 kinase beta-1

146

CURRICULUM VITAE
Jonathan David Rice, M.D.

Education

PhD, Physiology and Biophysics
Department of Physiology, University of Louisville
Thesis: The influence of miR-99a on mTOR signaling regulation in colorectal
cancer cell lines
Degree to be granted May 13, 2016

Doctor of Medicine
The University of Texas Medical Branch, Galveston, Texas
June 2011

Bachelor of Science, Deans Scholar degree in Chemistry with Honors
The University of Texas at Austin, Austin, Texas
May 2007

Bachelor of Science, Chemistry
The University of Oklahoma, Norman, Oklahoma
Transferred August 2003 to above

Training

The University of Louisville, Louisville Kentucky
PGY-3 Categorical Resident in General Surgery 2011-present
Chairman: Kelly McMasters, MD, PhD
Program Director: William Cheadle, MD
147

Publications

Rice J, Roberts H, Burton J, Pan J, States V, Rai SN, Galandiuk S. Assay
Reproducibility in Clinical Studies of Plasma miRNA. PLOS One. 2015 Apr
8;10(4):e0121948. doi: 10.1371/journal.pone.0121948.

Rice J, Roberts H, Rai SN, Galandiuk S. Housekeeping genes for studies of
plasma microRNA: A need for more precise standardization. Surgery. 2015
Nov;158(5):1345-51. doi: 10.1016/j.surg.2015.04.025. Epub 2015 Jun 18. PMID:
26094174

Billeter AT, Rice J, Druen D, Sklare S, Walker S, Gardner SA, Polk HC Jr.
Warming to 39ᵒC But Not to 37ᵒC Ameliorates the Effects on the Monocyte
Response by Hypothermia. Ann Surg. 2015 Feb 25. PMID: 25719808

Galandiuk S, Rice J, Deveaux P, Farmer R,. Chapter 69. Pneumstosis Cystoides
Intestinales. Current Therapy in Colon and Rectal Surgery 3rd. Edition. Fazio
VW, Delaney C, Church J, Ravi Kiran R (Eds.), Elsevier, London. In Press.

Galandiuk, S, Jorden J, Rice J, Deveaux P. Chapter 79. Acute and Chronic
Mesenteric Ischemia. Current Therapy in Colon and Rectal Surgery 3rd. Edition.
Fazio VW, Delaney C, Church J, Ravi Kiran R (Eds.), Elsevier, London. In
Press.
Boydston, A. J.; Rice, J. D.; Sanderson, M. D.; Dykhno, O. L.; Bielawski, C. W.
Synthesis and Study of Bidentate Benzimidazolylidene-Group 10 Metal
Complexes and Related Main-Chain Organometallic Polymers. Organometallics
2006, 25, 6087.DOI: 10.1021/om060494u
Deans Scholar Senior Thesis (Advisor: Jason Shear, PhD)
“Chemotaxis Studies and Characterization of Laminar Flow Streams Created
Using Laser-Induced Membrane Ablation” Rice, J.D.
Carter J, Rice J, Pan J, Roberts H, Eichenberger MR, Burton J, BA Galbraith N,
Jorden J, Deveaux P, Farmer RW, Williford A, Kanaan Z, Rai S, Galandiuk S. A
Highly Predictive Model for Diagnosis of Colorectal Neoplasms Using Plasma
MicroRNA: Improving Specificity and Sensitivity. Ann. Surg. 2016. To be
submitted April 2016.

148

Research

Price Institute of Surgical Research, The University of Louisville
Price Research Fellow
Lab of Susan Galandiuk, M.D.
July 2013-present

The University of Texas Medical Branch at Galveston, Research Associate
Lab of Celeste C. Finnerty, PhD
December 2010-January 2011
Data base analysis of the genomic responses to burns

The University of Texas Medical Branch at Galveston, Research Associate
Lab of Vinod K. Panchbhavi, M.D.
May 2008-September 2008
Properties of Achilles tendon rupture and repair

The University of Texas at Austin, Research Associate
Lab of Jason Shear, PhD
August 2006-May 2007
Completed studies on laminar flow in micro fluidics to aid in the design of
methods to study chemotaxis properties of neutrophil movement in a controlled
environment

The University of Texas at Austin, Research Associate
Lab of Christopher Bielawski, PhD
January 2005- August 2006

149

Researched new methods in route to determine new tertiary oxidation methods.
Developed methods for use of Benzobis(imidazolylidene)s in the creation of
novel fluorescence polymers.
Presented at 2006 Beckman Summer Research Symposium, Irvine California.
Presented at 2005, 2006 University of Texas at Austin Undergraduate Research
Day.

Honors/

UTMB Humanism Award in Pediatrics, Spring 2010

Awards

UTMB Honors in Pediatric Clerkship, Spring 2010
Arnold and Mabel Beckman Foundation Beckman Scholar, 2005-2006
UT Austin Dean’s Scholar Honors, 2004-2007
UT Austin University Honors Spring, 2004-2007
UT Austin Phi Beta Kappa member, Inducted 2006
UT Austin Undergraduate Research Fellowship, 2005-2006
University of Oklahoma Presidential Honor Roll, 2002-2003
University of Oklahoma Outstanding Freshman Honor Roll, Spring 2003
University of Oklahoma Gamma Phi Beta member, Inducted Spring 2003
Valedictorian, Fossil Ridge High School Fort Worth, TX, May 2002

Professional American College of Surgeons
Memberships American Medical Association
American Chemical Society
Greater Louisville Medical Society

Presentations:
Local:
Rice, J. Roberts H, Eichenberger MR, Galandiuk S. Comparing colorectal cell lines miRNA
profile. Research Louisville. Res-18. September16, 2014.
150

Roberts H, Rice R, Eichenberger MR, Pan J, Rai S, Galandiuk S. Plasma-based micro-RNA
panel specific for colorectal neoplasia. Research Louisville. UCE-66. September 16, 2014

Myers A, Roberts H, Rice R, Eichenberger MR, Galandiuk S. Identification of an internal
reference microRNA from the plasma of multiple cancer types. Research Louisville. UCE-63.
September, 2014

National:
Rice J, Roberts H, Eichenberger MR, Pan J, Rai S, Galandiuk S. Plasma housekeeping gene free
for all: a need for standardization. Academic Surgical Congress. Las Vegas, NV February, 2015.

TRPA1 mediates the effects of hypothermia on the monocyte inflammatory response. Galbraith
NJ, Billeter At, Lawson C, Rice JD, Polk HC. Academic Surgical Congress. Las Vegas, NV
February, 2015.

International:
Rice J. miR-99a influence on mTOR signaling regulation in colorectal cancer cell lines. 50th
meeting of the European Society of Surgical Research, Liverpool, UK. June 13, 2015

Activities

UTMB Clinical Preceptorship in the Department of Orthopedic Surgery, Summer
2008
UTMB Research Preceptorship in the Department of Orthopedic Surgery,
Summer 2008-Fall 2008
UTMB St. Vincent’s Free Clinic volunteer, 2007-2009
UTMB Orthopedic Surgery Student Organization Member, 2007-2009
UTMB Student Surgical Society Member, 2007-2011
UT Austin Cycling Team member, 2006-2007
UT Austin Undergraduate Research Investigator 2004-2007
151

UT Austin, Texas Union Film Committee 2004-2007
Austin Children’s Hospital Volunteer, Fall 2004, Fall 2005
Texas Union Theater Volunteer, Spring 2003-Spring 2007
UT Austin Undergraduate Research Focus Group member, Spring 2003-Spring
2007
University of Oklahoma Union Programming Board, 2002-2003
University of Oklahoma Honors College Council Member, 2002-2003

Interests

Current events, hockey, vinyl record collecting, cycling, film, literature,
percussion instruments, videogames and culinary arts

152

